

17. Cancer of the kidney

Table 17.1: Cancer of the kidney: number of new cases and deaths, and five-year relative survival proportions, by age at diagnosis and sex, Australia, 1992–1997

Age	New cases		Deaths		5-year relative survival (%)	
	Males	Females	Males	Females	Males	Females
0–19 years	102	106	17	14	82.2	85.1
20–29 years	29	23	6	5	81.2	75.4
30–39 years	178	118	41	22	78.3	82.2
40–49 years	638	362	184	82	71.9	77.7
50–59 years	1,207	640	423	195	67.0	72.4
60–69 years	1,984	1,111	943	514	58.2	58.7
70–79 years	1,894	1,404	1,143	837	50.4	46.6
80–89 years	641	632	496	500	44.1	30.3
90–99 years	45	70	36	65	65.4	20.8
All ages	6,718	4,466	3,289	2,234	59.9	57.5

Table 17.2: Cancer of the kidney relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	73.4	72.7–74.2	68.8	67.1–70.4	71.3	69.9–72.7	77.2	76.1–78.3
2	65.6	64.7–66.4	60.5	58.7–62.3	62.7	61.1–64.3	70.0	68.7–71.2
3	60.9	59.9–61.8	55.3	53.5–57.2	58.6	56.9–60.3	65.1	63.8–66.4
4	57.8	56.8–58.8	52.3	50.4–54.3	55.8	54.1–57.6	61.8	60.4–63.3
5	55.9	54.9–56.9	50.8	48.7–52.8	53.7	51.9–55.5	59.9	58.4–61.5
6	53.8	52.7–54.9	48.7	46.7–50.8	51.9	50.0–53.7	57.5	55.7–59.2
7	52.2	51.1–53.4	47.0	44.9–49.1	50.5	48.6–52.5	56.2	54.2–58.2
8	51.2	50.0–52.4	45.8	43.6–47.9	49.8	47.8–51.8		
9	50.0	48.8–51.3	45.1	42.8–47.3	48.4	46.3–50.4		
10	49.0	47.6–50.3	43.8	41.4–46.1	47.7	45.5–49.8		
11	48.3	46.8–49.8	43.3	40.9–45.7	46.7	44.4–49.0		
12	48.3	46.7–49.9	43.2	40.8–45.7	47.0	44.5–49.6		
13	47.8	46.1–49.6	43.2	40.7–45.7				
14	47.5	45.6–49.4	42.9	40.3–45.5				
15	47.0	44.8–49.1	42.5	39.7–45.2				

Table 17.3: Cancer of the kidney relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	70.9	70.0–71.9	67.4	65.4–69.4	69.8	68.1–71.5	73.5	72.1–74.9
2	62.6	61.6–63.6	58.8	56.6–61.0	61.0	59.1–62.9	65.6	64.1–67.1
3	58.5	57.4–59.6	55.0	52.8–57.2	56.7	54.8–58.7	61.4	59.8–63.0
4	55.7	54.6–56.8	51.9	49.6–54.2	54.1	52.1–56.2	58.8	57.1–60.5
5	54.0	52.8–55.1	49.4	47.1–51.7	52.7	50.6–54.7	57.5	55.7–59.4
6	52.1	50.8–53.3	48.0	45.6–50.4	50.7	48.6–52.8	55.3	53.2–57.3
7	50.7	49.4–52.0	46.9	44.4–49.3	49.2	47.1–51.4	54.1	51.9–56.4
8	49.3	47.9–50.6	45.6	43.1–48.1	47.9	45.7–50.1		
9	48.1	46.7–49.5	44.4	41.9–47.0	46.8	44.5–49.1		
10	47.3	45.8–48.8	43.5	40.9–46.2	46.2	43.8–48.6		
11	46.7	45.1–48.3	42.9	40.2–45.5	45.9	43.3–48.4		
12	46.2	44.5–47.9	42.4	39.7–45.1	45.4	42.7–48.2		
13	45.3	43.4–47.2	41.7	38.9–44.4				
14	45.1	43.1–47.1	41.4	38.6–44.3				
15	43.7	41.4–46.0	40.1	37.2–43.1				

Table 17.4: Cancer of the kidney relative survival proportions: period of diagnosis, persons, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	72.4	71.8–73.0	68.2	66.9–69.5	70.7	69.6–71.8	75.7	74.9–76.6
2	64.4	63.7–65.0	59.8	58.4–61.2	62.0	60.8–63.2	68.2	67.3–69.2
3	59.9	59.2–60.6	55.2	53.8–56.6	57.8	56.6–59.1	63.6	62.6–64.6
4	56.9	56.2–57.7	52.1	50.7–53.6	55.1	53.8–56.4	60.6	59.5–61.7
5	55.1	54.3–55.9	50.2	48.7–51.7	53.2	51.9–54.6	58.9	57.8–60.1
6	53.1	52.3–53.9	48.4	46.9–50.0	51.4	50.0–52.8	56.6	55.2–57.9
7	51.6	50.8–52.5	46.9	45.3–48.6	50.0	48.6–51.4	55.3	53.8–56.9
8	50.4	49.5–51.3	45.7	44.0–47.3	49.0	47.5–50.5		
9	49.2	48.3–50.2	44.8	43.1–46.5	47.7	46.2–49.2		
10	48.3	47.2–49.3	43.7	41.9–45.4	47.1	45.5–48.7		
11	47.6	46.5–48.7	43.1	41.3–44.9	46.4	44.6–48.1		
12	47.4	46.2–48.6	42.9	41.0–44.7	46.3	44.4–48.2		
13	46.7	45.5–48.0	42.5	40.6–44.4				
14	46.4	45.1–47.8	42.3	40.3–44.2				
15	45.5	44.0–47.1	41.4	39.4–43.5				

Table 17.5: Cancer of the kidney five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	85.0	80.2–89.8	88.9	81.3–96.4	83.7	73.7–93.8	82.2	74.3–90.0
20–29 years	70.1	58.5–81.7	67.1	45.2–89.0	58.3	35.9–80.6	81.2	65.4–97.0
30–39 years	74.5	70.2–78.8	70.8	61.5–80.1	72.9	65.8–80.0	78.3	71.8–84.7
40–49 years	66.3	63.6–68.9	63.0	57.4–68.6	60.4	55.5–65.4	71.9	68.0–75.7
50–59 years	60.1	58.1–62.1	52.8	48.9–56.7	56.4	52.8–60.1	67.0	63.9–70.0
60–69 years	54.7	53.0–56.5	49.6	46.2–53.1	53.8	50.7–56.8	58.2	55.5–60.9
70–79 years	46.5	44.4–48.7	38.5	34.3–42.8	45.6	41.8–49.3	50.4	47.1–53.7
80–89 years	41.4	36.5–46.3	39.6	29.1–50.1	37.9	29.3–46.4	44.1	37.0–51.1
90–99 years	38.3	10.1–66.5	*		34.1	0.0–79.4	65.4	21.5–109.4
All ages	55.9	54.9–56.9	50.8	48.7–52.8	53.7	51.9–55.5	59.9	58.4–61.5

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 17.6: Cancer of the kidney five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	86.2	82.0–90.5	84.9	76.6–93.1	87.6	80.7–94.5	85.1	77.7–92.5
20–29 years	78.2	68.3–88.1	84.4	68.0–100.3	75.2	59.1–91.3	75.4	56.1–94.7
30–39 years	79.0	73.7–84.4	79.3	68.7–89.9	74.5	63.6–85.5	82.2	75.2–89.3
40–49 years	70.3	66.8–73.8	60.1	52.2–67.9	65.8	59.3–72.3	77.7	73.0–82.4
50–59 years	63.2	60.6–65.7	52.4	47.4–57.3	61.3	56.8–65.9	72.4	68.6–76.2
60–69 years	53.2	51.1–55.3	47.0	43.1–51.0	52.0	48.4–55.6	58.7	55.4–62.1
70–79 years	44.2	41.9–46.4	40.2	35.4–44.9	42.7	38.7–46.6	46.6	43.3–50.0
80–89 years	31.3	27.3–35.2	30.7	21.9–39.6	32.8	25.8–39.8	30.3	24.6–36.1
90–99 years	24.1	7.7–40.5	58.4	0.0–118.8	12.4	0.0–36.1	20.8	0.6–41.0
All ages	54.0	52.8–55.1	49.4	47.1–51.7	52.7	50.6–54.7	57.5	55.7–59.4

Table 17.7: Cancer of the kidney five-year relative survival proportions: age at diagnosis by period of diagnosis, persons, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	85.7	82.5–88.8	86.8	81.1–92.4	86.1	80.3–91.9	83.7	78.3–89.1
20–29 years	74.3	66.7–81.9	76.0	62.1–89.9	68.4	55.0–81.7	78.5	66.1–90.9
30–39 years	76.1	72.8–79.5	74.0	66.9–81.1	73.3	67.4–79.3	79.9	75.1–84.6
40–49 years	67.7	65.6–69.8	62.0	57.4–66.6	62.3	58.4–66.3	74.0	71.0–77.0
50–59 years	61.2	59.7–62.8	52.7	49.6–55.7	58.3	55.5–61.2	68.9	66.5–71.3
60–69 years	54.1	52.8–55.5	48.6	46.0–51.1	53.1	50.7–55.4	58.4	56.3–60.5
70–79 years	45.5	43.9–47.0	39.3	36.1–42.4	44.3	41.5–47.0	48.7	46.3–51.0
80–89 years	35.9	32.8–39.0	35.0	28.2–41.8	35.0	29.6–40.5	36.7	32.2–41.1
90–99 years	30.3	15.4–45.2	32.1	0.0–66.8	21.5	0.0–45.1	37.0	16.2–57.7
All ages	55.1	54.3–55.9	50.2	48.7–51.7	53.2	51.9–54.6	58.9	57.8–60.1

Table 17.8: Cancer of the kidney five-year relative survival proportions: selected countries

Country	Relative survival (%) for males	Relative survival (%) for females
Australia (1987–1991)	54	53
Denmark (1985–1989)	36	33
England (1986–1990)	38	36
Europe* (1985–1989)	49	50
Finland (1985–1989)	48	51
Iceland (1985–1989)	46	39
Italy (1985–1989)	54	55
Scotland (1985–1989)	38	35
United States (1984–1990)	61	60
Wales (1986–1990)	35	28

* Weighted average.

Transitional cell carcinoma of the kidney

Table 17.9: Transitional cell carcinoma of the kidney relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	77.9	76.1–79.7	78.3	75.0–81.7	77.8	74.5–81.1	77.7	75.0–80.5
2	69.3	67.3–71.4	72.4	68.5–76.2	70.3	66.5–74.1	66.7	63.4–69.9
3	63.5	61.3–65.8	65.6	61.3–69.8	65.6	61.5–69.7	60.6	57.1–64.1
4	59.3	56.9–61.7	60.9	56.4–65.4	61.6	57.2–65.9	56.5	52.7–60.3
5	57.5	54.9–60.0	59.3	54.6–64.0	59.3	54.7–63.9	55.0	50.9–59.1
6	55.1	52.4–57.8	57.6	52.6–62.5	57.8	53.1–62.6	50.2	45.6–54.8
7	53.5	50.6–56.4	55.8	50.6–60.9	56.4	51.4–61.3	48.4	43.1–53.7
8	52.5	49.4–55.5	54.7	49.3–60.0	55.2	50.1–60.4		
9	51.1	47.9–54.4	52.9	47.4–58.5	54.3	48.9–59.7		
10	48.3	44.9–51.8	50.1	44.4–55.8	51.2	45.4–56.9		
11	48.0	44.3–51.7	50.4	44.5–56.4	49.5	43.3–55.8		
12	49.1	45.1–53.0	51.5	45.2–57.7	51.0	44.3–57.6		
13	47.1	42.8–51.4	49.9	43.5–56.4				
14	46.0	41.3–50.7	48.8	42.0–55.5				
15	47.1	42.0–52.3	50.0	42.8–57.1				

Table 17.10: Transitional cell carcinoma of the kidney relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	69.9	68.1–71.8	70.1	66.5–73.6	71.1	67.8–74.4	68.9	66.0–71.8
2	56.3	54.3–58.4	57.9	53.9–61.8	56.9	53.3–60.6	54.9	51.8–58.1
3	49.8	47.7–51.9	52.8	48.7–56.8	50.6	46.8–54.4	47.3	44.0–50.6
4	45.9	43.7–48.1	48.5	44.4–52.7	47.1	43.2–51.0	43.3	39.8–46.7
5	43.2	41.0–45.5	44.7	40.5–48.9	44.6	40.6–48.5	41.6	38.0–45.3
6	41.0	38.7–43.3	43.1	38.8–47.3	41.6	37.6–45.6	39.6	35.7–43.6
7	39.0	36.6–41.4	41.3	37.0–45.7	38.8	34.8–42.9	38.9	34.7–43.2
8	37.1	34.6–39.6	40.1	35.6–44.5	36.7	32.6–40.8		
9	36.4	33.8–39.0	39.7	35.1–44.2	35.7	31.4–39.9		
10	35.0	32.3–37.7	37.8	33.2–42.4	34.7	30.3–39.1		
11	34.1	31.3–37.0	36.9	32.2–41.6	33.8	29.1–38.5		
12	32.7	29.7–35.7	35.9	31.1–40.7	30.6	25.2–35.9		
13	30.7	27.5–33.9	33.7	28.8–38.5				
14	30.1	26.7–33.5	33.0	28.0–37.9				
15	29.1	25.4–32.8	31.9	26.8–37.0				

Table 17.11: Transitional cell carcinoma of the kidney five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	*		*		*		*	
20–29 years	75.5	32.8–100.7	67.1	13.4–100.7	*		*	
30–39 years	92.4	83.3–100.8	80.7	60.3–100.9	*		*	
40–49 years	81.3	74.6–88.1	81.0	68.1–93.9	84.4	73.5–95.3	78.2	66.5–89.9
50–59 years	67.0	61.4–72.6	63.3	53.8–72.8	64.2	53.9–74.6	73.3	64.3–82.4
60–69 years	58.4	54.3–62.4	59.8	52.2–67.4	63.1	55.9–70.3	54.7	48.3–61.0
70–79 years	48.8	44.2–53.4	51.9	42.8–60.9	51.3	43.0–59.6	44.3	37.0–51.6
80–89 years	37.6	28.1–47.1	45.7	25.8–65.5	21.0	7.2–34.8	44.8	30.0–59.6
90–99 years	58.8	0.0–128.1	*		*		88.8	0.0–195.5
All ages	57.5	54.9–60.0	59.3	54.6–64	59.3	54.7–63.9	55.0	50.9–59.1

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 17.12: Transitional cell carcinoma of the kidney five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	*		*		*		*	
20–29 years	*		—		*		*	
30–39 years	55.8	23.2–88.5	33.5	0.0–87.2	50.2	0.0–100.5	75.3	32.7–100.4
40–49 years	65.2	54.8–75.6	64.7	48.8–80.6	62.8	44.9–80.7	70.6	50.4–90.9
50–59 years	49.7	44.1–55.2	46.9	38.2–55.7	44.1	34.4–53.8	59.8	49.7–70.0
60–69 years	44.4	40.8–48.1	43.0	36.5–49.6	47.7	41.2–54.2	43.4	37.4–49.4
70–79 years	38.7	34.9–42.6	41.7	33.4–50.0	41.4	34.8–48.1	35.4	29.5–41.2
80–89 years	36.5	29.0–43.9	41.4	24.3–58.5	36.4	23.2–49.5	35.4	24.5–46.3
90–99 years	20.6	0.0–48.0	49.2	0.0–138.5	33.6	0.0–95.6	*	
All ages	43.2	41.0–45.5	44.7	40.5–48.9	44.6	40.6–48.5	41.6	38–45.3

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Renal cell carcinoma of the kidney

Table 17.13: Renal cell carcinoma of the kidney relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	76.6	75.7–77.4	70.9	68.9–72.9	74.5	72.8–76.1	80.3	79.1–81.5
2	69.0	68.0–69.9	61.6	59.3–63.8	66.0	64.1–67.8	74.0	72.6–75.3
3	64.4	63.3–65.4	56.6	54.3–58.9	61.7	59.8–63.7	69.4	67.9–70.8
4	61.2	60.1–62.3	53.7	51.3–56.1	58.9	56.9–60.9	65.9	64.2–67.5
5	58.9	57.7–60.1	51.7	49.2–54.2	56.3	54.2–58.4	63.6	61.9–65.4
6	56.4	55.2–57.7	49.1	46.5–51.6	54.1	51.9–56.2	61.5	59.5–63.5
7	54.6	53.3–56.0	47.0	44.4–49.6	52.5	50.3–54.8	59.9	57.6–62.3
8	53.4	52.0–54.9	45.3	42.7–48.0	51.8	49.5–54.1		
9	52.0	50.5–53.5	44.6	41.9–47.3	50.1	47.7–52.4		
10	51.0	49.4–52.7	43.2	40.4–46.0	49.7	47.2–52.2		
11	50.0	48.2–51.8	42.4	39.6–45.3	48.5	45.8–51.2		
12	49.6	47.7–51.6	42.0	39.0–44.9	48.6	45.6–51.6		
13	49.3	47.2–51.4	42.0	39.0–45.1				
14	48.7	46.4–51.1	41.6	38.4–44.7				
15	47.5	44.8–50.2	40.5	37.2–43.8				

Table 17.14: Renal cell carcinoma of the kidney relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	76.0	74.9–77.2	71.3	68.6–74.0	74.4	72.3–76.6	79.0	77.4–80.5
2	69.8	68.5–71.1	64.1	61.2–67.0	67.9	65.6–70.3	73.3	71.5–75.1
3	66.3	65.0–67.7	60.7	57.7–63.8	64.3	61.8–66.8	70.0	68.0–71.9
4	63.9	62.5–65.3	57.9	54.8–61.0	61.8	59.2–64.3	67.8	65.8–69.9
5	62.0	60.5–63.5	55.2	52.0–58.4	60.2	57.5–62.8	66.3	64.1–68.5
6	59.8	58.2–61.3	53.4	50.1–56.7	58.2	55.5–61.0	63.4	60.9–65.9
7	58.4	56.7–60.0	52.2	48.8–55.5	56.8	54.0–59.7	61.9	59.1–64.8
8	56.7	54.9–58.5	50.5	47.0–53.9	55.4	52.5–58.3		
9	54.9	53.0–56.8	48.8	45.3–52.3	53.8	50.8–56.8		
10	53.9	51.9–55.9	47.8	44.2–51.4	52.9	49.8–56.0		
11	53.0	50.8–55.1	46.6	42.9–50.2	52.5	49.2–55.8		
12	52.3	50.0–54.7	45.7	42.0–49.5	52.8	49.3–56.3		
13	51.3	48.7–53.8	45.0	41.2–48.8				
14	50.9	48.1–53.7	44.7	40.7–48.6				
15	48.3	45.0–51.6	42.3	38.2–46.4				

Table 17.15: Renal cell carcinoma of the kidney five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	80.4	60.0–100.5	*		67.0	13.4–100.5	78.1	50.8–100.4
20–29 years	70.4	57.5–83.3	64.1	35.5–92.7	53.3	29.4–77.2	87.5	73.7–100.6
30–39 years	74.7	70.0–79.3	74.1	63.6–84.7	73.0	65.4–80.6	76.7	69.7–83.7
40–49 years	66.0	63.0–68.9	61.6	55.2–67.9	59.1	53.6–64.6	72.5	68.4–76.6
50–59 years	62.4	60.2–64.7	54.7	50.1–59.3	58.7	54.7–62.7	68.9	65.6–72.2
60–69 years	57.4	55.4–59.5	50.3	46.1–54.5	55.5	52.0–59.1	62.1	59.0–65.1
70–79 years	50.5	47.8–53.2	38.5	32.9–44.0	50.5	45.7–55.2	54.7	50.8–58.7
80–89 years	53.7	46.6–60.8	53.4	35.9–70.9	50.1	37.6–62.6	54.6	44.7–64.5
90–99 years	47.1	1.1–93.1	*		38.1	0.0–109.3	68.5	2.3–134.6
All ages	58.9	57.7–60.1	51.7	49.2–54.2	56.3	54.2–58.4	63.6	61.9–65.4

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 17.16: Renal cell carcinoma of the kidney five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	65.7	38.2–93.3	80.1	45.0–100.1	50.1	0.0–100.2	53.4	4.7–100.2
20–29 years	78.6	67.8–89.5	81.5	62.3–100.3	78.4	61.5–95.3	75.8	54.9–96.7
30–39 years	80.0	74.3–85.6	82.6	71.4–93.8	75.3	63.9–86.7	82.4	75.0–89.8
40–49 years	71.9	68.2–75.7	60.5	51.1–69.9	68.5	61.5–75.6	77.5	72.6–82.5
50–59 years	69.3	66.4–72.2	57.2	50.9–63.4	69.3	64.1–74.4	76.0	72.0–80.1
60–69 years	61.7	59.1–64.4	54.4	49.0–59.9	58.3	53.8–62.9	68.8	64.8–72.8
70–79 years	54.2	51.1–57.4	47.0	40.0–53.9	52.0	46.3–57.8	57.9	53.4–62.5
80–89 years	37.3	31.2–43.5	37.6	21.4–53.9	42.0	30.8–53.1	34.1	25.7–42.6
90–99 years	52.1	15.3–88.8	87.4	0.0–192.3	*		65.5	11.8–119.2
All ages	62.0	60.5–63.5	55.2	52–58.4	60.2	57.5–62.8	66.3	64.1–68.5

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

18. Cancer of the brain

Table 18.1: Cancer of the brain: number of new cases and deaths, and five-year relative survival proportions, by age at diagnosis and sex, Australia, 1992–1997

Age	New cases		Deaths		5-year relative survival (%)	
	Males	Females	Males	Females	Males	Females
0–4 years	140	108	64	52	54.4	51.1
5–9 years	94	94	27	41	70.6	54.5
10–19 years	186	139	49	40	74.2	70.9
20–29 years	248	171	103	59	54.0	64.4
30–39 years	343	219	158	96	52.5	53.6
40–49 years	478	333	339	226	27.5	30.4
50–59 years	694	421	613	369	12.2	12.9
60–69 years	918	632	876	593	5.4	6.2
70–99 years	972	879	946	850	3.5	4.4
All ages	4,073	2,996	3,175	2,326	23.8	23.8

Table 18.2: Cancer of the brain relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	42.7	41.7–43.7	43.4	41.5–45.4	42.8	40.9–44.6	42.2	40.6–43.7
2	30.5	29.5–31.4	31.5	29.7–33.4	30.5	28.7–32.2	29.8	28.3–31.2
3	27.4	26.4–28.3	28.3	26.5–30.1	27.0	25.3–28.7	27.1	25.6–28.5
4	25.6	24.6–26.5	26.3	24.5–28.1	25.5	23.8–27.2	25.1	23.6–26.5
5	24.3	23.3–25.2	24.8	23.0–26.6	24.3	22.6–26.0	23.8	22.3–25.3
6	23.3	22.4–24.3	23.8	22.0–25.6	23.2	21.5–24.9	23.2	21.7–24.8
7	22.6	21.6–23.5	23.0	21.2–24.8	22.5	20.8–24.2	22.4	20.7–24.1
8	21.9	20.9–22.9	21.9	20.1–23.7	22.2	20.5–23.9		
9	21.3	20.3–22.3	21.4	19.6–23.2	21.5	19.7–23.2		
10	21.1	20.1–22.1	21.1	19.3–23.0	21.4	19.7–23.2		
11	21.1	20.0–22.1	21.2	19.3–23.1	21.2	19.4–23.0		
12	20.6	19.5–21.7	20.8	18.9–22.7	20.5	18.6–22.4		
13	20.5	19.4–21.7	20.9	19.0–22.8				
14	20.5	19.3–21.7	20.8	18.9–22.8				
15	20.4	19.1–21.7	20.8	18.8–22.8				

Table 18.3: Cancer of the brain relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	41.2	40.0–42.3	40.2	38.0–42.4	42.0	40.0–44.1	41.1	39.3–42.9
2	30.5	29.4–31.6	30.9	28.8–33.0	30.9	29.0–32.9	29.9	28.2–31.6
3	27.4	26.4–28.5	27.5	25.4–29.6	28.2	26.3–30.1	26.8	25.1–28.4
4	25.8	24.8–26.9	26.1	24.0–28.2	26.7	24.8–28.6	24.9	23.2–26.6
5	24.3	23.2–25.4	24.1	22.0–26.1	25.3	23.4–27.1	23.8	22.1–25.4
6	23.3	22.3–24.4	23.2	21.2–25.3	23.9	22.1–25.8	23.1	21.4–24.9
7	22.5	21.5–23.6	22.5	20.5–24.6	23.1	21.2–25.0	22.1	20.2–24.0
8	22.0	20.9–23.1	21.7	19.7–23.8	22.7	20.8–24.5		
9	21.4	20.2–22.5	20.9	18.8–22.9	22.2	20.3–24.1		
10	21.1	20.0–22.3	20.7	18.7–22.8	21.9	20.0–23.8		
11	21.0	19.8–22.2	20.5	18.4–22.6	21.9	19.9–23.8		
12	20.9	19.7–22.2	20.6	18.5–22.7	21.5	19.3–23.6		
13	20.7	19.4–22.0	20.3	18.2–22.4				
14	20.6	19.3–22.0	20.2	18.1–22.4				
15	20.6	19.2–22.0	20.2	18.0–22.4				

Table 18.4: Cancer of the brain relative survival proportions: period of diagnosis, persons, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	42.0	41.3–42.8	42.0	40.6–43.5	42.4	41.1–43.8	41.7	40.6–42.9
2	30.5	29.8–31.2	31.3	29.9–32.7	30.7	29.4–32.0	29.8	28.7–30.9
3	27.4	26.7–28.1	28.0	26.6–29.3	27.5	26.3–28.8	26.9	25.9–28.0
4	25.7	25.0–26.4	26.2	24.9–27.6	26.0	24.8–27.3	25.0	23.9–26.1
5	24.3	23.6–25.0	24.5	23.2–25.9	24.7	23.5–26.0	23.8	22.7–24.9
6	23.3	22.6–24.0	23.5	22.2–24.9	23.5	22.3–24.8	23.2	22.0–24.4
7	22.5	21.8–23.3	22.8	21.4–24.1	22.8	21.5–24.0	22.3	21.0–23.5
8	21.9	21.2–22.7	21.8	20.5–23.2	22.4	21.1–23.7		
9	21.3	20.6–22.1	21.2	19.8–22.5	21.8	20.5–23.1		
10	21.1	20.3–21.9	21.0	19.6–22.3	21.6	20.3–22.9		
11	21.0	20.2–21.8	20.9	19.5–22.3	21.5	20.2–22.8		
12	20.7	19.9–21.6	20.7	19.3–22.1	20.9	19.5–22.4		
13	20.6	19.7–21.5	20.6	19.2–22.0				
14	20.6	19.7–21.5	20.6	19.1–22.0				
15	20.5	19.5–21.5	20.5	19.0–22.0				

Table 18.5: Cancer of the brain five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	54.7	49.1–60.2	57.1	47.4–66.9	54.1	43.1–65.1	54.4	46.1–62.6
5–9 years	66.1	60.1–72.1	63.1	52.0–74.2	64.2	53.5–74.8	70.6	61.1–80.0
10–19 years	71.6	67.5–75.7	71.6	64.4–78.8	69.5	61.9–77.1	74.2	67.7–80.7
20–29 years	57.3	53.2–61.4	56.0	48.7–63.4	61.5	54.0–68.9	54.0	47.0–61.0
30–39 years	49.8	46.3–53.3	46.7	40.1–53.2	49.5	43.4–55.5	52.5	46.7–58.4
40–49 years	26.7	24.0–29.3	23.3	18.3–28.3	27.2	22.6–31.8	27.5	23.0–32.0
50–59 years	11.2	9.7–12.8	9.2	6.5–11.8	12.1	9.1–15.0	12.2	9.6–14.8
60–69 years	5.0	4.0–6.0	5.3	3.4–7.3	4.5	2.8–6.1	5.4	3.8–7.1
70 years and over	3.7	2.7–4.8	4.6	2.2–7.0	3.6	1.7–5.4	3.5	2.0–4.9
All ages	24.3	23.3–25.2	24.8	23–26.6	24.3	22.6–26	23.8	22.3–25.3

Table 18.6: Cancer of the brain five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	54.8	48.6–60.9	57.4	46.7–68.2	57.7	46.1–69.3	51.1	41.5–60.7
5–9 years	59.3	53.3–65.3	53.0	42.4–63.6	70.4	60.5–80.4	54.5	44.0–65.0
10–19 years	69.5	64.6–74.4	65.6	55.4–75.8	70.9	63.0–78.7	70.9	63.2–78.5
20–29 years	63.0	58.4–67.7	55.7	46.7–64.7	67.8	60.1–75.5	64.4	56.8–72.1
30–39 years	49.0	44.9–53.1	44.0	36.5–51.5	48.8	42.2–55.5	53.6	46.2–60.9
40–49 years	28.1	24.9–31.4	27.5	21.2–33.8	25.1	19.7–30.6	30.4	24.9–35.9
50–59 years	11.9	9.8–13.9	12.6	8.5–16.6	9.8	6.5–13.2	12.9	9.6–16.3
60–69 years	5.8	4.6–7.0	6.2	3.9–8.4	5.1	3.1–7.0	6.2	4.1–8.3
70 years and over	4.7	3.6–5.9	5.7	3.1–8.3	4.7	2.7–6.7	4.4	2.8–6.1
All ages	24.3	23.2–25.4	24.1	22.0–26.1	25.3	23.4–27.1	23.8	22.1–25.4

Table 18.7: Cancer of the brain five-year relative survival proportions: age at diagnosis by period of diagnosis, persons, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	54.7	50.6–58.8	57.3	50.1–64.5	55.8	47.8–63.7	53.0	46.7–59.2
5–9 years	62.6	58.3–66.8	57.7	49.9–65.4	67.4	60.1–74.7	62.3	55.1–69.5
10–19 years	70.7	67.6–73.9	69.5	63.6–75.3	70.2	64.7–75.6	72.8	67.8–77.7
20–29 years	59.7	56.6–62.8	55.9	50.2–61.6	64.4	59.0–69.8	58.2	53.0–63.5
30–39 years	49.5	46.8–52.1	45.5	40.6–50.4	49.2	44.7–53.6	52.9	48.4–57.5
40–49 years	27.3	25.2–29.3	25.0	21.1–29.0	26.4	22.9–29.9	28.7	25.2–32.1
50–59 years	11.5	10.2–12.7	10.4	8.2–12.6	11.2	9.0–13.4	12.5	10.4–14.5
60–69 years	5.4	4.6–6.1	5.7	4.2–7.2	4.7	3.5–6.0	5.8	4.5–7.1
70 years and over	4.2	3.5–5.0	5.2	3.4–6.9	4.2	2.8–5.6	4.0	2.9–5.1
All ages	24.3	23.6–25.0	24.5	23.2–25.9	24.7	23.5–26	23.8	22.7–24.9

Table 18.8: Cancer of the brain five-year relative survival proportions: selected countries

Country	Relative survival (%) for males	Relative survival (%) for females
Australia (1987–1991)	24	24
Denmark (1985–1989)	20	23
England (1986–1990)	13	15
Europe (1985–1989)	18	20
Finland (1985–1989)	31	28
Iceland (1985–1989)	17	16
Italy (1985–1989)	17	17
Scotland (1985–1989)	13	13
United States (1984–1990)	29	27
Wales (1986–1990)	15	16

* Weighted average.

19. Cancer of the thyroid

Table 19.1: Cancer of the thyroid: number of new cases and deaths, and five-year relative survival proportions, by age at diagnosis and sex, Australia, 1992–1997

Age	New cases		Deaths		5-year relative survival (%)	
	Males	Females	Males	Females	Males	Females
0–19 years	31	74	1	1	95.3	98.8
20–29 years	99	451	3	1	97.5	100.0
30–39 years	203	808	4	10	98.6	99.3
40–49 years	247	815	14	15	95.6	98.8
50–59 years	189	501	33	26	86.5	97.2
60–69 years	207	391	59	58	76.4	89.6
70–79 years	147	269	71	97	66.9	76.4
80–89 years	55	112	35	68	65.4	65.1
90–99 years	5	14	5	11	68.8*	68.7
All ages	1,183	3,435	225	287	87.9	95.6

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 19.2: Cancer of the thyroid relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	89.6	88.3–90.9	87.0	84.0–90.0	89.0	86.4–91.6	91.2	89.4–92.9
2	88.0	86.5–89.5	85.8	82.5–89.1	85.8	82.8–88.9	90.1	88.2–92.1
3	86.6	84.9–88.2	83.2	79.5–86.8	84.1	80.8–87.4	89.6	87.4–91.7
4	86.0	84.3–87.8	83.0	79.2–86.8	83.6	80.1–87.1	88.7	86.3–91.1
5	84.8	82.8–86.7	81.0	77.0–85.1	82.6	78.9–86.3	87.9	85.1–90.6
6	84.4	82.3–86.4	81.5	77.3–85.7	81.7	77.8–85.6	87.2	84.1–90.3
7	83.6	81.4–85.8	80.6	76.2–85.0	80.7	76.6–84.8	87.0	83.4–90.6
8	83.8	81.4–86.1	81.3	76.7–85.8	80.6	76.3–84.8		
9	83.4	80.9–85.9	81.0	76.3–85.7	80.0	75.6–84.4		
10	83.0	80.3–85.7	80.5	75.7–85.4	79.8	75.1–84.4		
11	83.5	80.6–86.4	80.7	75.7–85.7	80.8	76.0–85.6		
12	82.5	79.3–85.6	80.7	75.5–85.8	77.4	71.6–83.2		
13	81.0	77.4–84.5	79.2	73.8–84.5				
14	80.4	76.6–84.2	78.6	73.1–84.1				
15	81.3	77.2–85.3	79.5	73.8–85.1				

Table 19.3: Cancer of the thyroid relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	94.5	93.9–95.0	90.5	88.9–92.1	93.9	92.7–95.1	96.4	95.7–97.1
2	93.4	92.7–94.1	88.3	86.5–90.2	92.8	91.4–94.1	95.8	95.1–96.6
3	93.1	92.4–93.9	88.1	86.2–90.0	92.1	90.6–93.6	95.8	94.9–96.6
4	92.9	92.2–93.7	87.5	85.5–89.6	92.0	90.5–93.5	95.7	94.7–96.6
5	93.0	92.1–93.8	87.8	85.8–89.9	91.9	90.3–93.5	95.6	94.6–96.7
6	92.9	92.0–93.8	87.7	85.5–89.8	91.7	90.0–93.4	95.8	94.6–96.9
7	92.9	91.9–93.8	87.7	85.4–89.9	91.8	90.1–93.6	95.4	93.9–96.8
8	92.9	91.9–93.9	87.9	85.6–90.2	91.6	89.8–93.5		
9	93.0	91.9–94.0	87.6	85.2–90.0	92.0	90.1–93.8		
10	93.0	91.8–94.2	87.5	85.0–89.9	92.2	90.2–94.1		
11	93.3	92.1–94.6	88.0	85.5–90.5	92.2	90.1–94.3		
12	93.7	92.3–95.0	88.3	85.7–90.9	92.5	90.4–94.7		
13	94.1	92.7–95.5	88.8	86.1–91.4				
14	94.6	93.1–96.2	89.3	86.6–92.0				
15	94.8	93.1–96.5	89.4	86.6–92.3				

Table 19.4: Cancer of the thyroid relative survival proportions: period of diagnosis, persons, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	93.2	92.6–93.7	89.6	88.1–91.0	92.6	91.5–93.7	95.0	94.3–95.7
2	92.0	91.3–92.6	87.6	86.0–89.2	90.9	89.6–92.2	94.4	93.6–95.2
3	91.4	90.7–92.1	86.7	85.0–88.5	90.0	88.6–91.4	94.2	93.4–95.1
4	91.2	90.4–91.9	86.3	84.5–88.1	89.8	88.3–91.3	94.0	93.0–94.9
5	90.9	90.1–91.7	86.0	84.1–87.9	89.4	87.9–91.0	93.7	92.7–94.8
6	90.7	89.9–91.6	86.0	84.1–88.0	89.1	87.5–90.7	93.7	92.6–94.9
7	90.5	89.6–91.5	85.8	83.8–87.8	89.0	87.3–90.7	93.3	91.9–94.7
8	90.6	89.7–91.6	86.2	84.1–88.2	88.8	87.0–90.6		
9	90.6	89.5–91.6	85.9	83.7–88.0	88.9	87.1–90.8		
10	90.5	89.4–91.6	85.7	83.4–87.9	89.1	87.2–91.0		
11	90.9	89.7–92.1	86.1	83.8–88.4	89.3	87.3–91.3		
12	90.9	89.6–92.2	86.4	84.0–88.7	88.8	86.6–91.0		
13	90.9	89.5–92.3	86.3	83.9–88.7				
14	91.1	89.6–92.6	86.6	84.1–89.1				
15	91.5	89.8–93.2	86.9	84.3–89.5				

Table 19.5: Cancer of the thyroid five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	98.6	95.0–100.4	*		*		95.3	85.8–100.4
20–29 years	97.4	95.0–99.8	*		93.2	86.8–99.5	97.5	93.1–100.6
30–39 years	97.7	95.9–99.5	98.3	94.9–100.8	95.5	91.0–100.0	98.6	96.5–100.7
40–49 years	91.6	88.8–94.5	84.8	77.5–92.0	91.3	85.8–96.8	95.6	92.5–98.8
50–59 years	81.6	77.1–86.1	75.3	65.8–84.9	79.3	70.6–88.0	86.5	80.5–92.6
60–69 years	74.3	69.1–79.4	68.7	57.6–79.9	74.2	65.2–83.1	76.4	68.5–84.4
70–79 years	60.2	52.1–68.4	42.5	26.4–58.5	62.6	48.0–77.1	66.9	55.1–78.8
80–89 years	48.2	27.9–68.5	68.7	12.7–124.7	21.8	0.0–45.3	65.4	35.9–95.0
90–99 years	*		*		*		68.8	0.0–189.3
All ages	84.8	82.8–86.7	81.0	77–85.1	82.6	78.9–86.3	87.9	85.1–90.6

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 19.6: Cancer of the thyroid five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	97.9	95.7–100.1	98.5	95.1–100.2	95.8	89.7–100.2	98.8	96.2–100.2
20–29 years	99.3	98.7–100.0	97.8	95.8–99.7	99.9	99.1–100.2	100.0	99.6–100.2
30–39 years	99.4	98.9–99.9	98.8	97.4–100.2	99.9	99.3–100.4	99.3	98.6–100.1
40–49 years	97.7	96.7–98.7	93.9	90.6–97.2	98.1	96.3–100.0	98.8	97.6–99.9
50–59 years	95.1	93.4–96.8	90.8	86.2–95.3	94.5	91.2–97.9	97.2	95.1–99.2
60–69 years	84.1	80.9–87.3	75.6	68.2–83.0	80.1	73.7–86.6	89.6	85.4–93.8
70–79 years	65.0	59.8–70.3	52.2	42.0–62.4	56.8	47.1–66.4	76.4	68.7–84.0
80–89 years	47.8	37.8–57.8	27.2	12.4–42.0	41.8	24.0–59.6	65.1	48.7–81.5
90–99 years	48.0	0.0–98.3	*		*		68.7	0.0–137.6
All ages	93.0	92.1–93.8	87.8	85.8–89.9	91.9	90.3–93.5	95.6	94.6–96.7

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 19.7: Cancer of the thyroid five-year relative survival proportions: age at diagnosis by period of diagnosis, persons, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	98.1	96.2–100.0	98.9	96.2–100.3	97.2	93.0–100.3	97.9	94.6–100.2
20–29 years	99.0	98.3–99.6	98.4	96.9–99.9	98.5	97.1–100.0	99.5	98.6–100.3
30–39 years	99.1	98.5–99.6	98.7	97.4–100.0	99.2	98.2–100.1	99.2	98.5–99.9
40–49 years	96.1	95.1–97.2	91.1	87.9–94.3	96.3	94.3–98.3	98.0	96.9–99.2
50–59 years	91.3	89.4–93.1	85.9	81.4–90.3	90.2	86.7–93.8	94.3	92.1–96.6
60–69 years	80.6	77.8–83.4	73.2	66.9–79.4	77.8	72.5–83.0	85.2	81.3–89.1
70–79 years	63.5	59.1–67.9	49.4	40.7–58.1	58.7	50.7–66.7	73.2	66.7–79.7
80–89 years	48.3	39.2–57.3	32.4	17.6–47.3	36.5	21.8–51.2	65.6	51.2–79.9
90–99 years	72.7	21.1–124.2	*		*		68.7	8.9–128.6
All ages	90.9	90.1–91.7	86.0	84.1–87.9	89.4	87.9–91	93.7	92.7–94.8

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 19.8: Cancer of the thyroid five-year relative survival proportions: selected countries

Country	Relative survival (%) for males	Relative survival (%) for females
Australia (1987–1991)	88	96
Denmark (1985–1989)	59	72
England (1986–1990)	64	75
Europe* (1985–1989)	67	78
Finland (1985–1989)	83	88
Iceland (1985–1989)	93	94
Scotland (1985–1989)	72	74
United States (1984–1990)	91	97
Wales (1986–1990)	67	78

* Weighted average.

20. Cancers of unknown primary site

Table 20.1: Cancer of unknown primary site: number of new cases and deaths, and five-year relative survival proportions, by age at diagnosis and sex, Australia, 1992–1997

Age	New cases		Deaths		5-year relative survival (%)	
	Males	Females	Males	Females	Males	Females
0–19 years	27	22	14	7	47.2	68.7
20–29 years	45	34	23	24	46.8	29.5
30–39 years	144	174	97	126	32.2	26.6
40–49 years	481	390	365	313	23.9	19.7
50–59 years	1,104	751	924	623	16.7	15.8
60–69 years	2,480	1,629	2,195	1,424	12.2	12.7
70–79 years	2,919	2,457	2,699	2,264	9.9	9.0
80–89 years	1,574	2,105	1,485	2,026	9.9	5.7
90–99 years	192	433	189	423	4.9	7.5
All ages	8,966	7,995	7,991	7,230	13.4	11.5

Table 20.2: Cancer of unknown primary site relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	22.5	22.0–23.1	21.1	20.0–22.2	22.7	21.7–23.8	23.3	22.4–24.2
2	16.1	15.6–16.6	14.6	13.6–15.5	16.2	15.3–17.1	17.0	16.1–17.8
3	14.1	13.6–14.6	12.9	12.0–13.9	14.3	13.4–15.2	14.8	14.0–15.6
4	13.2	12.7–13.7	11.9	11.0–12.8	13.4	12.5–14.4	14.0	13.1–14.8
5	12.8	12.3–13.4	11.7	10.7–12.6	13.0	12.1–13.9	13.4	12.5–14.3
6	12.6	12.1–13.1	11.4	10.4–12.4	12.8	11.9–13.8	13.2	12.2–14.1
7	12.4	11.8–13.0	11.3	10.3–12.3	12.6	11.6–13.5	13.0	12.0–14.0
8	12.4	11.8–13.0	11.2	10.2–12.3	12.6	11.6–13.6		
9	12.6	12.0–13.2	11.4	10.3–12.5	12.9	11.8–13.9		
10	12.6	11.9–13.2	11.3	10.2–12.4	12.8	11.7–13.9		
11	12.7	12.0–13.4	11.4	10.2–12.5	13.1	11.9–14.2		
12	12.9	12.1–13.6	11.6	10.4–12.8	13.0	11.7–14.3		
13	13.0	12.2–13.9	11.7	10.5–13.0				
14	13.6	12.7–14.4	12.2	10.9–13.5				
15	14.0	13.0–14.9	12.6	11.2–13.9				

Table 20.3: Cancer of unknown primary site relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	21.9	21.3–22.5	21.2	20.0–22.3	21.9	20.8–23.0	22.5	21.5–23.4
2	14.7	14.1–15.2	14.0	13.0–15.0	14.8	13.8–15.7	15.0	14.2–15.9
3	12.5	12.0–13.0	11.8	10.8–12.7	12.4	11.5–13.3	13.1	12.3–13.9
4	11.5	11.0–12.0	10.8	9.8–11.7	11.6	10.7–12.5	12.0	11.1–12.8
5	11.0	10.5–11.5	10.4	9.5–11.4	10.9	10.0–11.8	11.5	10.6–12.3
6	10.8	10.3–11.3	10.1	9.1–11.0	10.7	9.8–11.6	11.5	10.6–12.4
7	10.8	10.2–11.3	9.9	9.0–10.9	10.8	9.8–11.7	11.3	10.3–12.3
8	10.8	10.2–11.4	10.1	9.1–11.1	10.7	9.8–11.7		
9	10.8	10.2–11.4	10.0	9.0–11.0	10.7	9.7–11.7		
10	10.9	10.2–11.5	10.1	9.0–11.2	10.7	9.7–11.8		
11	10.9	10.3–11.6	10.1	9.0–11.2	11.0	9.9–12.1		
12	11.0	10.3–11.7	10.1	9.0–11.3	11.3	10.2–12.5		
13	11.4	10.6–12.1	10.5	9.3–11.7				
14	11.5	10.7–12.4	10.6	9.4–11.9				
15	11.6	10.7–12.6	10.7	9.4–12.0				

Table 20.4: Cancer of unknown primary site relative survival proportions: period of diagnosis, persons, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	22.3	21.8–22.7	21.1	20.4–21.9	22.4	21.6–23.1	22.9	22.2–23.5
2	15.4	15.0–15.8	14.3	13.6–15.0	15.5	14.9–16.2	16.1	15.5–16.6
3	13.4	13.0–13.7	12.4	11.7–13.1	13.4	12.7–14.0	14.0	13.4–14.6
4	12.4	12.1–12.8	11.4	10.7–12.0	12.6	11.9–13.2	13.0	12.4–13.6
5	12.0	11.6–12.3	11.1	10.4–11.8	12.0	11.4–12.7	12.5	11.9–13.1
6	11.7	11.4–12.1	10.8	10.1–11.4	11.8	11.1–12.5	12.4	11.7–13.0
7	11.6	11.2–12.0	10.7	10.0–11.4	11.7	11.1–12.4	12.2	11.5–12.9
8	11.6	11.2–12.1	10.7	9.9–11.4	11.7	11.0–12.4		
9	11.7	11.3–12.2	10.7	10.0–11.5	11.9	11.1–12.6		
10	11.7	11.3–12.2	10.7	10.0–11.5	11.8	11.1–12.6		
11	11.9	11.4–12.3	10.8	10.0–11.5	12.1	11.3–12.9		
12	12.0	11.5–12.5	10.9	10.1–11.7	12.2	11.3–13.1		
13	12.2	11.7–12.8	11.1	10.2–12.0				
14	12.6	12.0–13.2	11.4	10.5–12.3				
15	12.8	12.2–13.5	11.6	10.7–12.6				

Table 20.5: Cancer of unknown primary site five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	52.4	41.0–63.9	44.9	26.5–63.3	69.5	48.5–90.5	47.2	28.0–66.5
20–29 years	49.2	40.4–58.0	47.9	32.7–63.1	51.6	36.2–67.0	46.8	30.8–62.7
30–39 years	35.9	31.1–40.7	33.0	24.1–41.8	41.5	33.3–49.7	32.2	24.3–40.1
40–49 years	20.6	18.2–23.1	13.7	9.8–17.7	21.9	17.5–26.4	23.9	19.9–27.9
50–59 years	15.4	14.1–16.8	15.0	12.6–17.3	14.7	12.4–16.9	16.7	14.3–19.0
60–69 years	10.9	10.1–11.8	9.0	7.5–10.5	11.0	9.6–12.4	12.2	10.7–13.6
70–79 years	9.6	8.7–10.4	8.9	7.3–10.5	9.6	8.1–11.1	9.9	8.5–11.3
80–89 years	9.2	7.6–10.8	8.3	5.1–11.4	8.2	5.5–10.8	9.9	7.4–12.4
90–99 years	5.0	0.4–9.6	10.6	0.0–25.2	*		4.9	0.0–11.1
All ages	12.8	12.3–13.4	11.7	10.7–12.6	13.0	12.1–13.9	13.4	12.5–14.3

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 20.6: Cancer of unknown primary site five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	55.3	44.4–66.3	46.8	29.9–63.7	55.7	36.9–74.5	68.7	48.0–89.4
20–29 years	34.0	25.2–42.8	39.6	25.0–54.3	31.5	16.1–46.9	29.5	14.1–44.8
30–39 years	28.0	23.4–32.5	28.2	19.2–37.3	29.2	20.7–37.7	26.6	19.7–33.4
40–49 years	19.4	16.7–22.0	16.1	11.2–21.0	21.2	16.5–25.9	19.7	15.5–23.9
50–59 years	14.2	12.6–15.7	12.9	10.3–15.5	12.9	10.2–15.6	15.8	12.9–18.7
60–69 years	10.9	9.9–11.8	8.6	7.0–10.3	10.8	9.1–12.5	12.7	11.0–14.5
70–79 years	8.6	7.8–9.4	8.9	7.3–10.5	8.0	6.6–9.4	9.0	7.7–10.3
80–89 years	6.1	5.2–7.1	5.6	3.7–7.5	7.1	5.3–9.0	5.7	4.2–7.1
90–99 years	6.5	3.3–9.8	6.6	0.0–14.0	5.5	0.2–10.8	7.5	2.8–12.3
All ages	11.0	10.5–11.5	10.4	9.5–11.4	10.9	10–11.8	11.5	10.6–12.3

Table 20.7: Cancer of unknown primary site five-year relative survival proportions: age at diagnosis by period of diagnosis, persons, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	53.9	46.0–61.8	46.0	33.5–58.4	61.6	47.5–75.7	56.6	42.1–71.1
20–29 years	42.1	35.8–48.4	43.7	33.1–54.3	42.3	31.2–53.5	39.7	28.5–50.9
30–39 years	32.0	28.6–35.3	30.8	24.4–37.1	36.1	30.1–42.1	28.9	23.7–34.1
40–49 years	20.1	18.3–21.8	14.8	11.7–17.8	21.6	18.3–24.8	22.0	19.1–24.9
50–59 years	14.9	13.9–15.9	14.1	12.4–15.8	14.0	12.2–15.7	16.3	14.5–18.1
60–69 years	10.9	10.2–11.5	8.8	7.8–9.9	10.9	9.8–12.0	12.4	11.3–13.5
70–79 years	9.1	8.5–9.7	8.9	7.8–10.1	8.8	7.8–9.8	9.5	8.5–10.4
80–89 years	7.3	6.4–8.1	6.5	4.9–8.2	7.5	6.0–9.0	7.3	6.0–8.6
90–99 years	6.1	3.4–8.8	7.8	1.0–14.6	4.3	0.1–8.4	6.7	2.8–10.5
All ages	12.0	11.6–12.3	11.1	10.4–11.8	12.0	11.4–12.7	12.5	11.9–13.1

Adenocarcinoma of unknown primary site

Table 20.8: Cancer of unknown primary site, adenocarcinoma relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	15.4	14.6–16.2	15.1	13.4–16.8	15.5	14.1–17.0	15.5	14.2–16.7
2	8.3	7.7–9.0	8.4	7.1–9.7	8.3	7.1–9.4	8.4	7.4–9.3
3	6.5	5.9–7.1	7.0	5.8–8.3	6.4	5.4–7.4	6.2	5.3–7.1
4	5.6	5.0–6.1	5.9	4.7–7.1	5.5	4.5–6.4	5.5	4.6–6.4
5	5.3	4.7–5.9	5.8	4.6–7.0	5.0	4.0–6.0	5.3	4.4–6.2
6	5.0	4.5–5.6	5.6	4.4–6.8	4.9	3.9–5.9	4.7	3.7–5.6
7	4.9	4.3–5.4	5.3	4.1–6.5	4.8	3.8–5.8	4.4	3.4–5.4
8	4.8	4.2–5.4	5.2	4.0–6.4	4.7	3.7–5.8		
9	4.9	4.2–5.5	5.4	4.1–6.6	4.8	3.7–5.8		
10	4.9	4.3–5.6	5.5	4.2–6.8	4.8	3.7–5.9		
11	5.0	4.3–5.7	5.5	4.1–6.9	4.9	3.7–6.0		
12	5.1	4.4–5.9	5.6	4.2–7.0	5.1	3.9–6.3		
13	5.1	4.3–5.9	5.6	4.2–7.1				
14	5.3	4.4–6.1	5.8	4.3–7.4				
15	5.6	4.7–6.5	6.2	4.6–7.8				

Table 20.9: Cancer of unknown primary site, adenocarcinoma relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	20.4	19.5–21.4	17.6	15.8–19.4	21.4	19.7–23.0	21.3	19.9–22.7
2	12.1	11.3–12.8	10.2	8.8–11.7	12.8	11.4–14.2	12.5	11.4–13.6
3	9.8	9.1–10.5	8.3	7.0–9.6	10.1	8.8–11.3	10.3	9.2–11.4
4	8.8	8.1–9.5	7.5	6.2–8.8	9.3	8.1–10.6	9.1	8.0–10.2
5	8.2	7.5–8.9	7.3	6.0–8.6	8.5	7.3–9.7	8.3	7.2–9.4
6	7.9	7.2–8.6	7.1	5.8–8.4	8.1	6.9–9.3	8.1	7.0–9.3
7	7.8	7.1–8.5	6.9	5.5–8.2	8.0	6.8–9.2	8.3	7.2–9.5
8	7.7	7.0–8.5	6.8	5.4–8.1	7.9	6.6–9.1		
9	7.4	6.6–8.1	6.4	5.1–7.7	7.6	6.3–8.8		
10	7.4	6.6–8.1	6.5	5.1–7.9	7.4	6.2–8.7		
11	7.3	6.5–8.1	6.4	5.1–7.8	7.4	6.0–8.7		
12	7.5	6.6–8.3	6.6	5.1–8.0	7.7	6.3–9.0		
13	7.7	6.8–8.7	6.8	5.3–8.3				
14	7.9	6.9–8.9	6.9	5.4–8.5				
15	8.1	7.0–9.1	7.1	5.5–8.7				

Table 20.10: Cancer of unknown primary site, adenocarcinoma five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	33.5	0.0–87.1	*		*		33.5	0.0–87.1
20–29 years	21.0	4.6–37.3	22.4	0.0–49.7	16.8	0.0–46.8	22.4	0.0–49.7
30–39 years	13.1	7.4–18.7	15.1	4.0–26.3	11.2	1.9–20.5	11.8	2.4–21.2
40–49 years	9.2	6.6–11.8	8.5	3.5–13.6	10.5	5.5–15.6	8.7	4.8–12.5
50–59 years	5.4	4.1–6.6	6.9	4.3–9.4	4.3	2.4–6.3	5.2	3.2–7.3
60–69 years	4.1	3.3–5.0	4.2	2.4–5.9	4.9	3.4–6.4	3.5	2.2–4.8
70–79 years	4.6	3.6–5.7	4.3	2.2–6.4	3.9	2.2–5.6	5.4	3.8–7.1
80–89 years	6.0	3.3–8.6	8.8	1.2–16.3	2.3	0.0–5.4	6.8	3.0–10.6
90–99 years	8.2	0.0–24.0	*		*		12.2	0.0–35.8
All ages	5.3	4.7–5.9	5.8	4.6–7	5.0	4–6	5.3	4.4–6.2

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 20.11: Cancer of unknown primary site, adenocarcinoma five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	*		*		*		*	
20–29 years	15.6	5.0–26.2	7.7	0.0–22.2	22.3	3.0–41.5	14.3	0.0–32.7
30–39 years	17.7	12.4–23.0	24.0	11.6–36.4	13.6	4.8–22.4	17.1	9.5–24.8
40–49 years	14.1	10.9–17.3	10.2	4.5–15.9	16.4	10.4–22.4	14.6	9.8–19.4
50–59 years	10.2	8.3–12.1	10.3	6.9–13.8	7.3	4.5–10.0	11.9	8.3–15.5
60–69 years	7.5	6.3–8.6	5.2	3.3–7.1	8.3	6.2–10.3	8.0	6.0–10.0
70–79 years	6.4	5.3–7.5	6.7	4.3–9.1	6.5	4.6–8.5	6.1	4.5–7.8
80–89 years	5.3	3.6–7.0	3.7	0.5–6.9	8.2	4.4–12.1	4.1	1.9–6.3
90–99 years	10.0	0.3–19.7	*		23.0	0.0–53.9	7.8	0.0–18.5
All ages	8.2	7.5–8.9	7.3	6.0–8.6	8.5	7.3–9.7	8.3	7.2–9.4

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

21. Hodgkin's disease

Table 21.1: Hodgkin's disease: number of new cases and deaths, and five-year relative survival proportions, by age at diagnosis and sex, Australia, 1992-1997

Age	New cases		Deaths		5-year relative survival (%)	
	Males	Females	Males	Females	Males	Females
0-4 years	184	151	12	8	95.7	95.1
5-9 years	265	274	14	21	96.1	92.4
10-19 years	211	189	28	7	87.9	95.6
20-29 years	169	90	19	13	88.5	86.6
30-39 years	107	65	34	17	68.5	77.9
40-49 years	134	93	68	39	56.3	62.0
50-59 years	94	93	59	55	51.1	52.6
60-69 years	32	40	28	33	21.8	23.4
70-99 years	2	1	2	0	*	*
All ages	1,198	996	264	193	82.6	84.4

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 21.2: Hodgkin's disease relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982-1997		1982-1986		1987-1991		1992-1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	90.7	89.6-91.8	89.6	87.6-91.7	90.0	87.9-92.0	92.0	90.4-93.7
2	85.9	84.6-87.3	83.7	81.2-86.2	84.8	82.3-87.3	88.6	86.7-90.6
3	82.8	81.3-84.3	79.9	77.1-82.7	81.7	78.9-84.4	86.0	83.8-88.3
4	80.7	79.1-82.3	77.0	74.1-80.0	79.8	77.0-82.7	84.4	82.0-86.8
5	78.8	77.2-80.5	74.1	71.0-77.2	79.1	76.1-82.0	82.6	79.9-85.3
6	76.9	75.1-78.7	72.1	68.9-75.4	77.7	74.7-80.8	79.9	76.7-83.0
7	76.1	74.2-77.9	71.4	68.0-74.7	76.7	73.5-79.9	79.4	76.0-82.9
8	75.4	73.5-77.4	70.7	67.3-74.1	76.0	72.7-79.2		
9	74.7	72.7-76.7	69.8	66.3-73.2	75.5	72.2-78.9		
10	74.1	72.0-76.2	69.6	66.1-73.2	74.2	70.7-77.8		
11	73.1	70.8-75.3	68.3	64.7-71.9	74.1	70.5-77.8		
12	73.0	70.6-75.3	68.5	64.8-72.2	72.7	68.5-76.9		
13	72.3	69.8-74.7	67.7	64.0-71.5				
14	71.9	69.3-74.5	67.4	63.6-71.2				
15	71.3	68.4-74.1	66.8	62.9-70.7				

Table 21.3: Hodgkin's disease relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	90.3	89.0–91.5	87.0	84.3–89.7	89.3	86.9–91.7	93.1	91.5–94.8
2	85.8	84.3–87.3	80.7	77.5–83.9	85.4	82.6–88.1	89.5	87.4–91.5
3	82.9	81.3–84.6	76.5	73.1–80.0	82.8	79.8–85.8	87.2	84.8–89.5
4	81.4	79.7–83.2	75.6	72.0–79.2	81.2	78.1–84.4	85.3	82.7–87.8
5	80.1	78.2–81.9	73.8	70.0–77.5	79.9	76.6–83.2	84.4	81.7–87.2
6	79.0	77.1–81.0	72.6	68.7–76.4	79.3	75.9–82.7	83.0	79.9–86.1
7	78.1	76.1–80.2	71.7	67.7–75.6	78.7	75.2–82.2	81.2	77.6–84.9
8	78.1	76.0–80.2	71.5	67.4–75.5	78.7	75.1–82.3		
9	77.8	75.6–80.0	71.7	67.6–75.8	77.9	74.2–81.6		
10	77.1	74.8–79.4	71.0	66.8–75.2	77.3	73.5–81.1		
11	77.0	74.6–79.5	70.7	66.4–75.0	77.7	73.7–81.6		
12	76.9	74.3–79.5	70.3	65.9–74.7	78.5	74.6–82.5		
13	76.4	73.7–79.1	70.0	65.6–74.5				
14	75.8	72.9–78.8	69.5	64.9–74.1				
15	76.4	73.3–79.5	70.0	65.4–74.6				

Table 21.4: Hodgkin's disease relative survival proportions: period of diagnosis, persons, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	90.5	89.7–91.3	88.6	86.9–90.2	89.7	88.1–91.2	92.5	91.4–93.7
2	85.9	84.9–86.9	82.4	80.5–84.4	85.0	83.2–86.9	89.0	87.6–90.4
3	82.8	81.7–83.9	78.5	76.3–80.7	82.1	80.1–84.2	86.5	84.9–88.1
4	81.0	79.8–82.2	76.4	74.1–78.7	80.4	78.3–82.6	84.8	83.0–86.6
5	79.4	78.1–80.6	74.0	71.6–76.4	79.4	77.2–81.6	83.5	81.5–85.4
6	77.8	76.5–79.2	72.3	69.8–74.8	78.4	76.1–80.7	81.3	79.1–83.5
7	77.0	75.6–78.3	71.5	68.9–74.0	77.6	75.2–79.9	80.2	77.7–82.8
8	76.6	75.1–78.0	71.0	68.4–73.6	77.2	74.7–79.6		
9	76.0	74.5–77.5	70.6	67.9–73.2	76.5	74.1–79.0		
10	75.4	73.8–76.9	70.2	67.5–72.9	75.6	73.0–78.2		
11	74.8	73.1–76.4	69.3	66.5–72.1	75.7	73.0–78.3		
12	74.6	72.9–76.4	69.2	66.4–72.1	75.3	72.4–78.2		
13	74.0	72.2–75.9	68.7	65.8–71.5				
14	73.6	71.6–75.6	68.3	65.3–71.2				
15	73.4	71.3–75.5	68.1	65.1–71.1				

Table 21.5: Hodgkin's disease five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	91.5	88.8–94.2	84.7	78.4–90.9	93.4	89.4–97.4	95.7	92.4–98.9
5–9 years	89.7	87.4–92.1	84.9	80.1–89.6	88.9	84.7–93.2	96.1	93.5–98.7
10–19 years	87.3	84.3–90.3	87.1	82.0–92.3	86.9	81.1–92.7	87.9	83.1–92.7
20–29 years	83.5	79.6–87.4	74.1	65.2–83.1	84.3	77.8–90.7	88.5	82.9–94.0
30–39 years	73.5	68.0–78.9	76.4	67.8–85.1	72.8	63.3–82.4	68.5	57.6–79.5
40–49 years	48.8	42.6–55.0	36.5	26.2–46.8	51.4	40.3–62.5	56.3	45.9–66.8
50–59 years	36.3	28.3–44.3	29.5	16.7–42.4	28.8	15.8–41.8	51.1	37.3–64.8
60–69 years	24.6	8.3–40.9	*		35.9	7.3–64.6	21.8	0.0–47.9
70 years and over	60.8	0.0–169.7	*		123.4	0.0–320.9	*	
All ages	78.8	77.2–80.5	74.1	71–77.2	79.1	76.1–82	82.6	79.9–85.3

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 21.6: Hodgkin's disease five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	93.4	90.6–96.1	90.8	85.0–96.7	93.3	88.4–98.2	95.1	91.1–99.1
5–9 years	91.4	89.2–93.7	87.6	82.6–92.5	94.0	90.6–97.4	92.4	88.9–95.8
10–19 years	92.6	89.8–95.3	85.9	78.9–92.9	93.6	89.4–97.9	95.6	91.9–99.4
20–29 years	85.0	79.6–90.3	82.3	70.5–94.0	83.2	73.2–93.2	86.6	78.6–94.6
30–39 years	73.1	65.9–80.3	67.0	54.9–79.1	76.9	63.1–90.6	77.9	67.1–88.7
40–49 years	57.8	51.0–64.6	54.7	42.4–67.1	55.6	44.1–67.1	62.0	50.4–73.7
50–59 years	38.6	31.1–46.1	27.8	15.8–39.7	32.8	20.2–45.4	52.6	39.7–65.4
60–69 years	16.5	6.3–26.6	14.7	0.0–30.7	10.7	0.0–25.1	23.4	2.4–44.4
70 years and over	*		*		*		*	
All ages	80.1	78.2–81.9	73.8	70.0–77.5	79.9	76.6–83.2	84.4	81.7–87.2

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 21.7: Hodgkin's disease five-year relative survival proportions: age at diagnosis by period of diagnosis, persons, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	92.3	90.4–94.2	87.2	82.9–91.6	93.4	90.3–96.5	95.4	92.9–98.0
5–9 years	90.5	88.9–92.2	86.0	82.6–89.5	91.3	88.5–94.1	94.2	92.0–96.4
10–19 years	89.7	87.6–91.8	86.7	82.5–90.9	90.2	86.6–93.9	91.6	88.5–94.7
20–29 years	84.0	80.8–87.1	76.6	69.4–83.8	83.9	78.5–89.4	87.8	83.2–92.4
30–39 years	73.3	68.9–77.6	73.0	65.9–80.1	74.0	66.1–81.9	71.8	63.7–79.9
40–49 years	52.7	48.1–57.3	44.3	36.2–52.4	53.4	45.4–61.4	58.5	50.7–66.4
50–59 years	37.6	32.1–43.0	28.6	19.8–37.4	30.9	21.8–40.0	51.7	42.3–61.2
60–69 years	19.4	10.6–28.2	11.2	0.0–23.5	21.5	6.5–36.5	22.5	6.1–38.9
70 years and over	57.4	0.0–129.9	*		48.1	0.0–135.4	*	
All ages	79.4	78.1–80.6	74.0	71.6–76.4	79.4	77.2–81.6	83.5	81.5–85.4

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 21.8: Hodgkin's disease five-year relative survival proportions: selected countries

Country	Relative survival (%) for males	Relative survival (%) for females
Australia (1987–1991)	79	80
Denmark (1985–1989)	71	73
England (1986–1990)	—	—
Europe* (1985–1989)	72	74
Finland (1985–1989)	75	74
Iceland (1985–1989)	92	100
Italy (1985–1989)	69	71
Scotland (1985–1989)	68	67
United States (1984–1990)	79	86
Wales (1986–1990)	—	—

* Weighted average.

22. Non-Hodgkin's lymphoma

Table 22.1: Non-Hodgkin's lymphoma: number of new cases and deaths, and five-year relative survival proportions, by age at diagnosis and sex, Australia, 1992-1997

Age	New cases		Deaths		5-year relative survival (%)	
	Males	Females	Males	Females	Males	Females
0-19 years	152	69	33	14	76.5	79.5
20-29 years	147	99	60	28	60.8	72.8
30-39 years	357	172	152	57	59.8	75.3
40-49 years	478	351	226	113	62.3	75.9
50-59 years	790	553	340	238	61.6	65.8
60-69 years	1,145	852	619	438	55.3	54.7
70-79 years	1,235	1,128	864	704	43.6	45.3
80-89 years	512	618	437	490	29.7	32.8
90-99 years	36	77	34	69	19.0	12.0
All ages	4,852	3,919	2,765	2,151	54.6	55.8

Table 22.2: Non-Hodgkin's lymphoma relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982-1997		1982-1986		1987-1991		1992-1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	72.4	71.8-73.1	71.4	70.0-72.8	71.6	70.4-72.8	73.4	72.5-74.4
2	63.8	63.0-64.5	61.9	60.4-63.5	62.9	61.6-64.3	65.2	64.1-66.3
3	59.0	58.2-59.8	56.5	54.9-58.1	57.9	56.5-59.3	61.0	59.9-62.1
4	55.4	54.6-56.2	52.7	51.0-54.4	54.3	52.8-55.7	57.5	56.3-58.7
5	52.3	51.4-53.1	49.6	47.9-51.4	51.1	49.6-52.5	54.6	53.2-55.9
6	50.5	49.6-51.4	47.3	45.6-49.1	49.9	48.4-51.4	52.5	51.1-53.9
7	48.3	47.4-49.3	45.0	43.2-46.8	47.9	46.3-49.5	50.5	48.9-52.2
8	46.8	45.8-47.8	44.0	42.2-45.9	46.1	44.5-47.7		
9	45.5	44.5-46.6	42.1	40.2-44.0	45.4	43.8-47.1		
10	44.3	43.2-45.4	41.1	39.2-43.0	44.0	42.3-45.7		
11	43.1	41.9-44.2	39.7	37.8-41.6	43.2	41.4-45.0		
12	42.3	41.0-43.5	39.0	37.0-41.0	42.5	40.5-44.5		
13	41.5	40.1-42.8	38.2	36.2-40.2				
14	41.2	39.7-42.6	37.9	35.8-40.0				
15	41.1	39.5-42.7	37.8	35.7-40.0				

Table 22.3: Non-Hodgkin's lymphoma relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	74.0	73.3–74.7	72.9	71.4–74.4	73.9	72.6–75.2	74.5	73.5–75.5
2	65.2	64.4–66.0	62.8	61.2–64.4	65.3	63.9–66.8	66.3	65.2–67.5
3	60.4	59.6–61.2	57.3	55.6–59.0	60.3	58.8–61.9	62.1	60.9–63.3
4	56.8	55.9–57.7	53.1	51.3–54.8	57.2	55.6–58.7	58.6	57.3–59.9
5	54.0	53.0–54.9	49.9	48.1–51.7	54.6	53.0–56.2	55.8	54.3–57.2
6	51.8	50.8–52.7	48.0	46.2–49.8	52.1	50.5–53.8	53.7	52.1–55.2
7	49.5	48.5–50.5	46.1	44.3–48.0	49.7	48.0–51.4	51.5	49.7–53.4
8	47.6	46.5–48.6	44.2	42.3–46.1	47.7	46.0–49.5		
9	46.3	45.2–47.4	42.7	40.8–44.7	46.7	45.0–48.5		
10	44.5	43.3–45.6	40.9	38.9–42.9	45.0	43.2–46.9		
11	43.4	42.2–44.7	40.0	38.0–42.0	44.0	42.0–45.9		
12	42.4	41.0–43.7	39.2	37.1–41.2	42.5	40.3–44.7		
13	41.4	39.9–42.8	38.4	36.3–40.5				
14	40.5	39.0–42.1	37.6	35.5–39.7				
15	40.0	38.3–41.7	37.1	34.9–39.4				

Table 22.4: Non-Hodgkin's lymphoma relative survival proportions: period of diagnosis, persons, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	73.1	72.6–73.6	72.1	71.1–73.1	72.7	71.8–73.5	73.9	73.2–74.6
2	64.4	63.9–64.9	62.3	61.2–63.4	64.0	63.0–65.0	65.7	64.9–66.5
3	59.6	59.1–60.2	56.9	55.7–58.1	59.0	58.0–60.0	61.5	60.7–62.3
4	56.0	55.4–56.6	52.9	51.7–54.1	55.6	54.5–56.6	58.0	57.1–58.9
5	53.0	52.4–53.7	49.8	48.5–51.0	52.6	51.6–53.7	55.1	54.1–56.1
6	51.1	50.4–51.7	47.6	46.4–48.9	50.9	49.8–52.0	53.0	52.0–54.1
7	48.9	48.2–49.6	45.5	44.2–46.8	48.7	47.6–49.9	51.0	49.8–52.2
8	47.2	46.4–47.9	44.1	42.8–45.4	46.8	45.7–48.0		
9	45.9	45.1–46.7	42.4	41.1–43.8	46.0	44.8–47.2		
10	44.4	43.6–45.2	41.0	39.6–42.4	44.5	43.2–45.7		
11	43.2	42.4–44.1	39.8	38.5–41.2	43.5	42.2–44.9		
12	42.3	41.4–43.2	39.1	37.6–40.5	42.5	41.0–43.9		
13	41.4	40.4–42.4	38.3	36.8–39.7				
14	40.8	39.8–41.9	37.8	36.3–39.3				
15	40.5	39.4–41.7	37.5	35.9–39.0				

Table 22.5: Non-Hodgkin's lymphoma five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	72.2	68.6–75.7	67.3	60.4–74.1	71.1	64.8–77.5	76.5	71.0–82.0
20–29 years	60.0	56.1–63.9	65.8	58.0–73.5	55.3	48.2–62.5	60.8	55.1–66.6
30–39 years	60.0	57.4–62.6	67.0	61.6–72.3	57.2	52.6–61.8	59.8	56.0–63.6
40–49 years	62.1	60.0–64.2	61.3	56.8–65.9	62.2	58.6–65.8	62.3	59.2–65.5
50–59 years	58.7	56.8–60.5	53.1	49.5–56.7	59.0	55.7–62.4	61.6	58.8–64.4
60–69 years	50.8	49.2–52.5	45.3	42.0–48.5	49.2	46.3–52.0	55.3	52.7–57.9
70–79 years	40.0	38.2–41.9	36.1	32.4–39.8	37.8	34.6–41.0	43.6	40.6–46.5
80–89 years	28.3	24.8–31.7	23.6	16.1–31.1	28.6	22.7–34.5	29.7	24.5–34.9
90–99 years	16.4	3.8–28.9	*		27.8	0.0–58.2	19.0	0.0–38.4
All ages	52.3	51.4–53.1	49.6	47.9–51.4	51.1	49.6–52.5	54.6	53.2–55.9

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 22.6: Non-Hodgkin's lymphoma five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	76.1	71.2–81.0	68.3	58.7–77.9	79.5	70.9–88.1	79.5	72.0–87.0
20–29 years	72.1	67.3–77.0	69.9	59.6–80.3	73.3	64.7–81.8	72.8	65.7–79.9
30–39 years	73.3	70.1–76.4	72.8	66.7–78.9	71.1	65.2–76.9	75.3	70.6–80.1
40–49 years	71.4	69.1–73.8	62.9	57.7–68.0	71.0	66.8–75.3	75.9	72.6–79.2
50–59 years	64.4	62.4–66.4	58.7	54.8–62.6	67.5	63.9–71.0	65.8	62.6–68.9
60–69 years	53.5	51.7–55.2	49.5	46.1–52.9	54.6	51.6–57.6	54.7	51.9–57.5
70–79 years	42.1	40.3–43.8	36.1	32.7–39.5	42.1	39.0–45.1	45.3	42.5–48.0
80–89 years	30.7	27.9–33.6	29.8	23.7–35.9	27.6	22.6–32.7	32.8	28.6–37.0
90–99 years	16.1	7.0–25.2	7.0	0.0–20.6	29.4	6.9–51.9	12.0	0.5–23.5
All ages	54.0	53.0–54.9	49.9	48.1–51.7	54.6	53–56.2	55.8	54.3–57.2

Table 22.7: Non-Hodgkin's lymphoma five-year relative survival proportions: age at diagnosis by period of diagnosis, persons, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–19 years	73.5	70.6–76.3	67.6	62.0–73.2	73.7	68.5–78.8	77.5	73.0–81.9
20–29 years	64.4	61.3–67.4	67.2	61.0–73.4	61.7	56.1–67.3	65.3	60.7–69.8
30–39 years	64.7	62.7–66.7	69.3	65.3–73.4	61.9	58.3–65.5	65.0	62.0–68.0
40–49 years	65.9	64.3–67.4	62.0	58.6–65.4	65.6	62.8–68.4	67.9	65.6–70.3
50–59 years	61.2	59.8–62.5	55.6	53.0–58.3	62.7	60.3–65.2	63.4	61.3–65.5
60–69 years	52.1	50.9–53.3	47.3	44.9–49.6	51.7	49.6–53.8	55.0	53.1–56.9
70–79 years	41.1	39.8–42.4	36.1	33.6–38.6	40.0	37.8–42.2	44.5	42.4–46.5
80–89 years	29.7	27.5–31.9	27.5	22.8–32.3	28.1	24.2–31.9	31.5	28.3–34.8
90–99 years	16.2	8.8–23.6	4.2	0.0–12.4	28.8	10.8–46.9	14.6	4.7–24.5
All ages	53.0	52.4–53.7	49.8	48.5–51	52.6	51.6–53.7	55.1	54.1–56.1

Table 22.8: Non-Hodgkin's lymphoma five-year relative survival proportions: selected countries

Country	Relative survival (%) for males	Relative survival (%) for females
Australia (1987–1991)	55	56
Denmark (1985–1989)	46	49
England (1986–1990)	41	45
Europe* (1985–1989)	49	49
Finland (1985–1989)	46	47
Iceland (1985–1989)	51	72
Italy (1985–1989)	47	49
Scotland (1985–1989)	45	42
United States (1984–1990)	47	57
Wales (1986–1990)	38	39

* Weighted average.

23. Leukaemia

Table 23.1: Leukaemia: number of new cases and deaths, and five-year relative survival proportions, by age at diagnosis and sex, Australia, 1992–1997

Age	New cases		Deaths		5-year relative survival (%)	
	Males	Females	Males	Females	Males	Females
0–4 years	309	281	86	62	71.8	76.2
5–9 years	179	127	51	31	69.2	75.7
10–19 years	241	161	114	65	51.8	56.2
20–29 years	211	177	108	82	47.3	52.9
30–39 years	288	214	150	103	48.7	49.6
40–49 years	430	336	190	177	54.6	47.0
50–59 years	773	490	392	246	51.0	49.2
60–69 years	1,382	842	918	484	38.0	44.3
70–99 years	2,833	2,363	2,325	1,871	25.7	29.3
All ages	6,646	4,991	4,334	3,121	41.2	43.2

Table 23.1: Leukaemia: number of new cases and deaths, and five-year relative survival proportions, by age at diagnosis and sex, Australia, 1992–1997

Age	New cases		Deaths		5-year relative survival (%)	
	Males	Females	Males	Females	Males	Females
0–4 years	309	281	86	62	71.8	76.2
5–9 years	179	127	51	31	69.2	75.7
10–19 years	241	161	114	65	51.8	56.2
20–29 years	211	177	108	82	47.3	52.9
30–39 years	288	214	150	103	48.7	49.6
40–49 years	430	336	190	177	54.6	47.0
50–59 years	773	490	392	246	51.0	49.2
60–69 years	1,382	842	918	484	38.0	44.3
70–99 years	2,833	2,363	2,325	1,871	25.7	29.3
All ages	6,646	4,991	4,334	3,121	41.2	43.2

Table 23.2: Leukaemia relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	65.6	64.8–66.4	64.8	63.3–66.3	66.1	64.7–67.5	65.7	64.5–66.9
2	54.9	54.0–55.7	53.6	52.0–55.2	56.1	54.6–57.6	54.8	53.5–56.1
3	48.8	48.0–49.7	47.0	45.3–48.7	50.2	48.7–51.8	49.0	47.6–50.3
4	44.6	43.7–45.5	42.6	40.9–44.3	46.2	44.7–47.8	44.5	43.1–45.9
5	41.5	40.5–42.4	39.4	37.6–41.1	43.3	41.7–44.9	41.2	39.7–42.7
6	38.5	37.5–39.4	36.9	35.2–38.7	40.1	38.5–41.8	37.9	36.3–39.6
7	36.4	35.5–37.4	35.2	33.4–36.9	37.8	36.1–39.5	35.9	34.1–37.7
8	34.7	33.7–35.8	33.6	31.8–35.4	36.0	34.3–37.6		
9	33.5	32.4–34.6	32.0	30.2–33.8	35.0	33.3–36.8		
10	32.3	31.2–33.4	30.6	28.8–32.5	34.1	32.3–35.9		
11	31.3	30.2–32.5	29.5	27.6–31.4	33.5	31.6–35.4		
12	30.6	29.3–31.8	28.8	26.9–30.6	32.8	30.7–34.9		
13	30.0	28.6–31.3	28.3	26.3–30.2				
14	29.9	28.4–31.3	28.2	26.2–30.1				
15	29.8	28.3–31.4	28.1	26.1–30.2				

Table 23.3: Leukaemia relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	63.3	62.4–64.2	61.9	60.1–63.7	65.2	63.5–66.8	62.9	61.5–64.3
2	54.3	53.3–55.2	52.1	50.2–54.0	56.1	54.4–57.9	54.3	52.8–55.8
3	48.8	47.8–49.8	46.0	44.1–47.9	50.6	48.8–52.4	49.2	47.7–50.8
4	45.1	44.1–46.2	42.3	40.4–44.3	46.6	44.7–48.4	45.9	44.3–47.6
5	42.5	41.4–43.5	39.4	37.5–41.4	44.2	42.4–46.1	43.2	41.5–44.9
6	40.0	38.9–41.0	36.3	34.3–38.2	42.1	40.2–44.0	41.1	39.2–42.9
7	37.9	36.8–39.0	34.2	32.2–36.2	40.1	38.1–42.0	38.8	36.7–40.9
8	36.1	35.0–37.3	32.6	30.6–34.6	38.1	36.2–40.1		
9	34.9	33.6–36.1	31.4	29.4–33.4	36.9	34.9–38.9		
10	33.7	32.4–35.0	30.1	28.1–32.2	35.9	33.8–38.0		
11	33.1	31.8–34.4	29.6	27.6–31.7	35.2	33.1–37.4		
12	32.4	31.0–33.8	29.0	26.9–31.1	34.6	32.3–37.0		
13	32.1	30.6–33.6	28.7	26.5–30.8				
14	32.0	30.4–33.6	28.6	26.4–30.8				
15	32.6	30.9–34.3	29.1	26.9–31.4				

Table 23.4: Leukaemia relative survival proportions: period of diagnosis, persons, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	64.6	64.0–65.2	63.6	62.4–64.7	65.7	64.7–66.8	64.5	63.6–65.4
2	54.6	54.0–55.3	53.0	51.7–54.2	56.1	55.0–57.3	54.6	53.6–55.6
3	48.8	48.2–49.5	46.6	45.3–47.8	50.4	49.2–51.6	49.1	48.1–50.1
4	44.8	44.1–45.5	42.5	41.2–43.8	46.4	45.2–47.6	45.1	44.0–46.2
5	41.9	41.2–42.6	39.4	38.1–40.7	43.7	42.5–44.9	42.1	40.9–43.2
6	39.1	38.4–39.8	36.6	35.3–37.9	41.0	39.7–42.2	39.3	38.0–40.5
7	37.1	36.3–37.8	34.8	33.4–36.1	38.8	37.5–40.1	37.1	35.7–38.5
8	35.3	34.6–36.1	33.1	31.8–34.5	36.9	35.6–38.2		
9	34.1	33.3–34.9	31.7	30.4–33.1	35.8	34.5–37.1		
10	32.9	32.1–33.7	30.4	29.0–31.8	34.9	33.5–36.2		
11	32.1	31.2–33.0	29.6	28.2–30.9	34.2	32.8–35.7		
12	31.4	30.5–32.3	28.9	27.4–30.3	33.6	32.0–35.2		
13	30.9	29.9–31.9	28.5	27.0–29.9				
14	30.8	29.7–31.9	28.4	26.9–29.8				
15	31.0	29.9–32.2	28.6	27.1–30.1				

Table 23.5: Leukaemia five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	72.0	68.9–75.0	67.3	61.7–72.9	76.6	71.5–81.6	71.8	66.4–77.1
5–9 years	71.2	66.8–75.6	71.6	63.4–79.9	73.8	66.3–81.2	69.2	62.0–76.5
10–19 years	47.4	43.5–51.4	38.8	31.7–45.8	50.5	43.7–57.2	51.8	45.0–58.6
20–29 years	39.7	35.4–44.0	34.2	26.6–41.9	36.3	29.0–43.6	47.3	40.0–54.7
30–39 years	40.9	37.1–44.8	34.8	27.6–41.9	37.3	30.5–44.0	48.7	42.5–54.9
40–49 years	46.9	43.6–50.2	35.3	28.8–41.8	46.1	40.5–51.6	54.6	49.4–59.8
50–59 years	47.9	45.4–50.3	44.2	39.9–48.6	46.8	42.4–51.2	51.0	47.0–55.0
60–69 years	40.3	38.5–42.2	38.4	35.0–41.7	44.1	40.9–47.2	38.0	35.0–41.1
70 years and over	27.9	26.3–29.5	28.4	25.3–31.4	30.2	27.4–33.0	25.7	23.3–28.0
All ages	41.5	40.5–42.4	39.4	37.6–41.1	43.3	41.7–44.9	41.2	39.7–42.7

Table 23.6: Leukaemia five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	72.9	69.5–76.4	67.8	61.2–74.5	72.7	66.6–78.8	76.2	70.7–81.7
5–9 years	73.7	68.8–78.7	71.2	61.8–80.5	72.9	64.3–81.5	75.7	67.3–84.0
10–19 years	51.9	47.1–56.7	43.3	34.8–51.7	55.6	47.5–63.6	56.2	47.7–64.6
20–29 years	45.8	40.8–50.7	35.7	26.4–45.1	44.7	36.2–53.3	52.9	45.2–60.6
30–39 years	42.0	37.6–46.3	27.9	20.8–34.9	46.8	39.0–54.5	49.6	42.2–56.9
40–49 years	40.4	36.6–44.1	29.0	22.0–36.0	39.7	33.1–46.4	47.0	41.2–52.7
50–59 years	44.9	41.9–47.9	41.8	36.3–47.2	42.7	37.3–48.2	49.2	44.3–54.1
60–69 years	43.5	41.2–45.8	40.6	36.5–44.8	45.2	41.2–49.1	44.3	40.5–48.2
70 years and over	32.1	30.5–33.8	32.7	29.4–35.9	35.2	32.2–38.2	29.3	26.8–31.9
All ages	42.5	41.4–43.5	39.4	37.5–41.4	44.2	42.4–46.1	43.2	41.5–44.9

Table 23.7: Leukaemia five-year relative survival proportions: age at diagnosis by period of diagnosis, persons, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	72.4	70.1–74.7	67.5	63.2–71.8	74.9	71.0–78.8	73.9	70.1–77.7
5–9 years	72.3	69.0–75.6	71.4	65.3–77.6	73.4	67.7–79.0	72.0	66.5–77.5
10–19 years	49.3	46.2–52.3	40.7	35.2–46.1	52.5	47.4–57.7	53.5	48.2–58.8
20–29 years	42.3	39.0–45.6	34.8	28.9–40.8	40.0	34.4–45.6	49.9	44.6–55.2
30–39 years	41.4	38.5–44.3	31.5	26.5–36.5	41.5	36.4–46.6	49.1	44.4–53.8
40–49 years	44.1	41.6–46.6	32.5	27.8–37.3	43.6	39.3–47.8	51.2	47.3–55.0
50–59 years	46.7	44.8–48.6	43.3	39.9–46.7	45.2	41.8–48.6	50.2	47.1–53.3
60–69 years	41.5	40.1–43.0	39.3	36.6–41.9	44.5	42.0–46.9	40.4	38.0–42.8
70 years and over	30.0	28.8–31.1	30.5	28.3–32.7	32.6	30.5–34.7	27.4	25.7–29.2
All ages	41.9	41.2–42.6	39.4	38.1–40.7	43.7	42.5–44.9	42.1	40.9–43.2

**Table 23.8: Leukaemia five-year relative survival proportions:
selected countries**

Country	Relative survival (%) for males	Relative survival (%) for females
Australia (1987–1991)	41	43
Denmark (1985–1989)	29	27
England (1986–1990)	53	27
Europe* (1985–1989)	35	36
Finland (1985–1989)	37	34
Iceland (1985–1989)	20	20
Italy (1985–1989)	26	31
Scotland (1985–1989)	30	25
United States (1984–1990)	44	42
Wales (1986–1990)	48	27

* Weighted average.

Acute lymphatic leukaemia

Table 23.9: Acute lymphatic leukaemia relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	77.0	75.3–78.8	75.8	72.4–79.1	77.4	74.3–80.6	77.7	74.8–80.5
2	66.0	64.0–68.0	63.2	59.4–67.0	67.0	63.5–70.5	67.2	64.0–70.4
3	60.5	58.4–62.6	58.0	54.1–62.0	61.2	57.5–64.9	61.7	58.3–65.1
4	56.7	54.5–58.8	54.5	50.5–58.5	57.5	53.8–61.3	57.6	54.1–61.1
5	54.3	52.1–56.5	52.4	48.4–56.4	55.3	51.5–59.1	54.6	50.8–58.3
6	52.4	50.1–54.6	51.0	47.0–55.1	52.8	49.0–56.6	53.0	49.1–56.8
7	51.7	49.4–54.0	49.6	45.6–53.7	53.1	49.2–56.9	51.5	47.4–55.7
8	50.9	48.6–53.2	49.2	45.1–53.3	52.0	48.1–55.9		
9	50.9	48.5–53.2	48.7	44.6–52.9	52.3	48.4–56.3		
10	50.9	48.5–53.2	48.6	44.4–52.8	52.5	48.6–56.5		
11	51.0	48.6–53.4	48.8	44.6–53.0	52.6	48.6–56.6		
12	51.3	48.9–53.7	49.0	44.8–53.2	53.1	49.0–57.1		
13	51.5	49.0–53.9	49.2	44.9–53.4				
14	51.8	49.3–54.3	49.5	45.2–53.8				
15	52.1	49.7–54.6	49.8	45.5–54.1				

Table 23.10: Acute lymphatic leukaemia relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	77.7	75.6–79.7	76.6	72.7–80.6	79.8	76.2–83.4	76.9	73.7–80.1
2	67.4	65.1–69.7	64.1	59.7–68.6	69.7	65.5–73.8	68.0	64.4–71.5
3	63.2	60.8–65.6	59.6	55.0–64.2	65.4	61.1–69.8	63.9	60.2–67.6
4	60.2	57.7–62.7	55.9	51.2–60.6	62.2	57.7–66.6	61.8	57.9–65.6
5	58.0	55.5–60.5	53.1	48.3–57.8	60.9	56.4–65.4	59.1	55.0–63.1
6	57.3	54.7–59.9	52.5	47.7–57.2	60.5	56.0–65.1	57.7	53.4–62.0
7	56.2	53.5–58.8	50.7	45.9–55.5	60.3	55.7–64.9	55.9	51.2–60.6
8	55.3	52.6–57.9	49.9	45.0–54.7	59.3	54.6–63.9		
9	54.9	52.2–57.6	49.9	45.1–54.8	58.5	53.8–63.2		
10	54.8	52.1–57.6	50.0	45.1–54.9	58.2	53.4–62.9		
11	54.8	52.0–57.6	50.1	45.1–55.0	58.1	53.3–62.9		
12	54.6	51.7–57.4	49.9	44.9–54.8	57.7	52.7–62.7		
13	54.0	51.1–57.0	49.2	44.3–54.2				
14	54.3	51.4–57.3	49.5	44.5–54.5				
15	54.7	51.7–57.7	49.8	44.8–54.9				

Table 23.11: Acute lymphatic leukaemia five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	78.9	75.8–82.0	72.3	66.6–78.0	86.6	82.1–91.2	78.1	72.4–83.7
5–9 years	76.9	72.3–81.5	79.3	71.1–87.4	76.2	68.2–84.2	75.9	68.1–83.6
10–19 years	47.5	42.5–52.4	41.9	32.9–51.0	47.8	39.6–55.9	51.3	42.6–59.9
20–29 years	35.5	28.1–42.9	28.8	16.0–41.5	39.2	26.7–51.8	38.3	25.4–51.3
30–39 years	30.5	22.1–38.9	22.8	7.9–37.6	17.8	4.9–30.7	41.9	28.6–55.2
40–49 years	20.4	11.6–29.2	9.3	0.0–26.5	14.1	2.6–25.6	27.5	12.9–42.0
50–59 years	18.2	8.9–27.4	16.7	0.0–34.1	24.3	7.2–41.3	8.4	0.0–22.3
60–69 years	7.8	2.7–12.9	10.8	0.7–20.9	8.1	0.0–16.9	3.9	0.0–11.1
70 years and over	6.6	1.6–11.7	3.5	0.0–10.4	3.0	0.0–9.0	12.1	2.1–22.2
All ages	54.3	52.1–56.5	52.4	48.4–56.4	55.3	51.5–59.1	54.6	50.8–58.3

Table 23.12: Acute lymphatic leukaemia five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	78.1	74.6–81.6	73.3	66.5–80.1	80.7	74.6–86.8	79.1	73.4–84.9
5–9 years	80.3	75.2–85.3	77.5	67.8–87.3	78.1	69.1–87.1	83.7	75.5–91.9
10–19 years	61.7	55.6–67.9	52.7	41.6–63.8	68.1	57.7–78.4	63.6	53.2–74.1
20–29 years	43.3	33.7–52.9	37.1	18.9–55.4	43.0	26.5–59.4	48.8	33.9–63.8
30–39 years	32.2	22.3–42.2	11.6	0.0–23.9	52.8	30.3–75.4	36.8	22.4–51.2
40–49 years	9.9	1.2–18.5	*		14.4	0.0–32.9	10.4	0.0–23.1
50–59 years	16.1	7.2–24.9	6.9	0.0–19.9	17.9	2.0–33.8	17.9	3.7–32.0
60–69 years	14.6	6.6–22.5	7.5	0.0–17.4	16.5	1.6–31.3	20.7	5.3–36.2
70 years and over	10.1	4.2–16.1	4.3	0.0–12.5	11.2	0.7–21.8	12.8	3.3–22.4
All ages	58.0	55.5–60.5	53.1	48.3–57.8	60.9	56.4–65.4	59.1	55–63.1

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Acute myeloid leukaemia

Table 23.13: Acute myeloid leukaemia relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	35.5	34.0–37.0	33.3	30.3–36.2	36.0	33.3–38.6	36.4	34.1–38.6
2	21.9	20.6–23.2	20.6	18.0–23.2	21.8	19.4–24.1	22.8	20.8–24.8
3	17.3	16.1–18.5	15.5	13.1–17.8	17.0	14.8–19.2	18.6	16.7–20.5
4	15.1	13.9–16.3	13.6	11.3–15.8	14.2	12.1–16.3	16.9	14.9–18.8
5	14.5	13.3–15.7	12.7	10.5–15.0	13.8	11.7–15.9	16.1	14.2–18.1
6	14.0	12.8–15.3	12.0	9.8–14.3	13.5	11.4–15.6	15.8	13.7–17.9
7	13.9	12.6–15.2	11.9	9.6–14.2	13.2	11.1–15.4	16.1	13.9–18.3
8	13.8	12.5–15.2	12.1	9.8–14.5	13.0	10.8–15.1		
9	14.3	12.9–15.6	12.7	10.2–15.1	13.2	11.0–15.5		
10	14.4	13.0–15.9	12.8	10.2–15.3	13.4	11.1–15.8		
11	14.7	13.1–16.2	12.9	10.3–15.5	14.0	11.6–16.5		
12	15.2	13.6–16.8	13.3	10.6–16.0	14.6	12.0–17.1		
13	15.7	14.0–17.4	13.9	11.1–16.7				
14	15.4	13.6–17.3	13.7	10.8–16.6				
15	16.1	14.1–18.0	14.3	11.2–17.3				

Table 23.14: Acute myeloid leukaemia relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	34.5	32.9–36.1	32.1	29.0–35.2	35.2	32.3–38.1	35.5	33.1–37.9
2	23.4	21.9–24.8	20.1	17.4–22.8	23.9	21.2–26.5	25.0	22.8–27.2
3	19.3	17.9–20.7	14.9	12.5–17.3	19.9	17.4–22.4	21.5	19.4–23.7
4	17.0	15.7–18.4	13.1	10.8–15.5	17.0	14.6–19.5	19.5	17.3–21.7
5	16.3	14.9–17.7	12.3	10.0–14.6	16.4	14.0–18.8	18.8	16.6–21.1
6	16.1	14.7–17.5	11.6	9.3–13.9	16.4	14.0–18.9	18.9	16.5–21.2
7	15.7	14.3–17.1	10.7	8.4–12.9	16.3	13.8–18.8	19.5	17.0–21.9
8	15.5	14.0–16.9	10.3	8.1–12.6	16.2	13.7–18.8		
9	15.4	13.9–16.9	10.5	8.2–12.9	15.9	13.3–18.5		
10	15.6	14.0–17.2	10.6	8.2–13.0	16.2	13.5–18.8		
11	16.0	14.4–17.7	10.8	8.4–13.3	16.7	14.0–19.4		
12	15.8	14.0–17.5	10.4	8.0–12.8	17.2	14.4–20.0		
13	16.3	14.5–18.1	10.8	8.3–13.3				
14	16.3	14.4–18.3	10.8	8.2–13.4				
15	16.9	14.9–19.0	11.2	8.5–13.8				

Table 23.15: Acute myeloid leukaemia five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	39.8	29.7–50.0	37.0	15.2–58.8	46.8	29.9–63.7	35.2	19.8–50.6
5–9 years	41.0	28.3–53.8	28.6	4.9–52.3	53.0	29.2–76.7	40.8	22.2–59.3
10–19 years	42.7	34.5–50.8	29.8	17.5–42.0	45.4	30.3–60.6	54.8	40.9–68.7
20–29 years	35.1	28.1–42.2	31.6	18.8–44.4	20.8	10.3–31.3	47.7	35.6–59.7
30–39 years	31.0	25.1–36.8	24.4	14.0–34.9	29.9	19.8–39.9	37.2	27.5–46.8
40–49 years	26.1	21.1–31.1	13.7	5.4–22.1	22.2	14.3–30.0	35.8	27.4–44.2
50–59 years	14.1	10.9–17.3	14.1	8.2–20.0	10.7	5.7–15.6	16.7	11.0–22.3
60–69 years	6.3	4.6–8.0	5.8	2.7–8.8	6.9	3.9–9.9	6.2	3.4–8.9
70 years and over	3.1	2.0–4.1	3.9	1.4–6.5	2.9	1.0–4.8	2.8	1.3–4.3
All ages	14.5	13.3–15.7	12.7	10.5–15	13.8	11.7–15.9	16.1	14.2–18.1

Table 23.16: Acute myeloid leukaemia five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	42.3	30.0–54.5	29.5	7.8–51.2	36.1	15.9–56.3	56.5	36.8–76.2
5–9 years	47.2	32.8–61.5	38.5	12.0–65.0	58.9	35.5–82.3	37.5	10.1–64.9
10–19 years	39.2	31.0–47.4	30.8	16.3–45.3	38.2	25.4–51.1	48.7	33.9–63.5
20–29 years	43.7	36.7–50.7	28.9	16.6–41.3	42.5	29.8–55.1	53.4	42.6–64.1
30–39 years	34.4	28.3–40.5	21.3	11.4–31.2	34.2	24.6–43.8	43.0	31.2–54.8
40–49 years	25.3	20.2–30.5	8.3	1.9–14.7	23.0	13.7–32.4	35.9	27.7–44.2
50–59 years	15.3	11.7–19.0	11.6	5.6–17.5	11.9	6.0–17.7	21.7	15.1–28.4
60–69 years	9.2	6.8–11.5	9.8	5.2–14.4	8.3	4.4–12.2	9.6	5.7–13.5
70 years and over	2.7	1.7–3.7	4.3	1.8–6.8	2.4	0.6–4.2	2.0	0.7–3.2
All ages	16.3	14.9–17.7	12.3	10.0–14.6	16.4	14–18.8	18.8	16.6–21.1

Chronic lymphatic leukaemia

Table 23.17: Chronic lymphatic leukaemia relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	88.5	87.5–89.6	88.9	86.9–90.9	87.9	86.0–89.8	88.7	87.1–90.4
2	83.1	81.8–84.4	82.9	80.4–85.5	83.8	81.5–86.1	82.6	80.5–84.6
3	77.7	76.2–79.2	77.1	74.2–80.0	78.4	75.8–81.1	77.5	75.2–79.9
4	72.5	70.8–74.2	72.5	69.3–75.7	74.8	71.9–77.7	70.0	67.3–72.8
5	67.8	66.0–69.6	68.0	64.6–71.5	70.2	67.1–73.4	64.8	61.7–67.9
6	62.7	60.7–64.7	63.5	59.9–67.1	65.2	61.9–68.5	58.8	55.2–62.3
7	57.8	55.7–59.9	60.1	56.3–63.9	58.9	55.5–62.4	53.9	49.7–58.2
8	53.6	51.4–55.9	55.5	51.6–59.5	54.6	51.1–58.2		
9	50.1	47.7–52.5	50.9	46.9–54.9	51.9	48.3–55.6		
10	46.2	43.6–48.7	46.4	42.3–50.5	48.6	44.6–52.5		
11	42.9	40.2–45.6	42.3	38.2–46.4	46.6	42.3–50.9		
12	39.5	36.6–42.3	38.7	34.5–42.8	43.6	38.7–48.5		
13	36.4	33.3–39.5	35.7	31.5–39.9				
14	35.4	32.0–38.7	34.7	30.4–39.0				
15	33.7	30.0–37.4	33.0	28.5–37.6				

Table 23.18: Chronic lymphatic leukaemia relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	89.8	88.6–91.0	89.3	86.9–91.7	91.6	89.6–93.6	88.7	86.8–90.7
2	85.5	84.0–87.0	84.2	81.1–87.2	87.2	84.7–89.8	84.9	82.5–87.2
3	80.4	78.7–82.2	78.7	75.2–82.2	82.9	80.0–85.9	79.5	76.7–82.2
4	76.1	74.1–78.0	73.6	69.7–77.4	79.7	76.4–82.9	74.6	71.4–77.7
5	72.7	70.6–74.8	70.9	66.7–75.0	76.2	72.6–79.8	70.5	67.0–74.1
6	68.2	65.8–70.5	64.7	60.3–69.0	72.6	68.8–76.4	66.8	62.7–70.9
7	63.8	61.2–66.3	62.1	57.5–66.7	67.3	63.3–71.3	60.1	54.8–65.3
8	59.9	57.2–62.6	58.5	53.7–63.3	62.9	58.7–67.1		
9	56.7	53.8–59.6	55.0	50.0–59.9	60.1	55.6–64.5		
10	53.4	50.3–56.5	51.8	46.7–56.9	56.5	51.8–61.2		
11	50.5	47.1–53.8	48.6	43.4–53.8	54.0	48.8–59.1		
12	48.9	45.2–52.5	46.8	41.4–52.1	53.1	47.2–59.0		
13	47.3	43.3–51.2	45.5	40.0–51.1				
14	46.4	42.1–50.8	44.7	39.0–50.5				
15	47.1	42.3–51.9	45.4	39.3–51.5				

Table 23.19: Chronic lymphatic leukaemia five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	*		*		*		*	
5–9 years	*		*		*		*	
10–19 years	50.3	0.0–100.6	*		*		*	
20–29 years	67.1	13.4–100.7	*		*		*	
30–39 years	83.8	72.1–95.4	92.4	76.7–100.8	72.0	48.2–95.9	89.6	74.8–100.8
40–49 years	79.9	74.5–85.4	74.4	62.8–86.0	80.8	72.1–89.4	83.2	74.4–92.0
50–59 years	78.7	75.4–81.9	75.0	69.0–81.0	81.6	75.9–87.3	78.4	72.9–83.8
60–69 years	72.1	69.3–74.9	73.3	68.0–78.5	73.7	69.1–78.3	68.6	63.7–73.5
70 years and over	55.4	52.1–58.6	56.1	49.8–62.3	59.3	53.7–64.9	50.9	45.7–56.2
All ages	67.8	66.0–69.6	68.0	64.6–71.5	70.2	67.1–73.4	64.8	61.7–67.9

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 23.20: Chronic lymphatic leukaemia five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	*		*		*		*	
5–9 years	*		*		—		*	
10–19 years	*		*		*		*	
20–29 years	*		*		*		*	
30–39 years	82.9	64.8–100.4	57.4	20.6–94.2	*		*	
40–49 years	88.0	81.8–94.3	81.1	65.2–97.0	85.2	73.4–96.9	93.8	86.9–100.7
50–59 years	87.8	83.9–91.6	85.6	78.2–93.1	90.6	84.4–96.8	87.6	81.5–93.8
60–69 years	79.4	76.2–82.7	77.9	71.5–84.3	80.1	74.8–85.4	80.0	74.5–85.5
70 years and over	63.6	60.4–66.8	62.3	56.2–68.4	69.3	63.9–74.7	58.9	53.7–64.1
All ages	72.7	70.6–74.8	70.9	66.7–75.0	76.2	72.6–79.8	70.5	67–74.1

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Chronic myeloid leukaemia

Table 23.21: Chronic myeloid leukaemia relative survival proportions: period of diagnosis, males, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	73.3	71.4–75.1	75.1	71.4–78.7	73.2	69.9–76.6	72.3	69.5–75.1
2	57.1	55.0–59.2	55.5	51.3–59.8	57.6	53.8–61.4	57.5	54.4–60.7
3	45.5	43.3–47.7	40.5	36.3–44.7	48.6	44.6–52.5	46.2	42.9–49.4
4	38.3	36.1–40.5	31.2	27.2–35.3	41.1	37.1–45.0	40.7	37.3–44.1
5	32.3	30.1–34.5	23.7	19.9–27.5	35.5	31.5–39.4	35.8	32.2–39.5
6	26.6	24.4–28.8	20.2	16.5–23.8	29.1	25.3–32.9	29.2	25.3–33.2
7	24.1	21.8–26.3	17.9	14.3–21.5	26.1	22.4–29.9	27.8	23.4–32.1
8	22.2	19.9–24.5	16.1	12.6–19.6	24.3	20.5–28.1		
9	20.1	17.7–22.5	14.0	10.7–17.4	22.5	18.7–26.3		
10	18.7	16.3–21.2	13.0	9.6–16.4	21.1	17.2–24.9		
11	16.9	14.3–19.4	11.8	8.5–15.1	18.5	14.3–22.7		
12	16.3	13.5–19.0	11.3	8.0–14.6	18.4	13.9–22.8		
13	15.4	12.4–18.3	10.7	7.4–14.0				
14	14.6	11.4–17.8	10.2	6.9–13.6				
15	13.3	9.7–16.9	9.3	5.9–12.6				

Table 23.22: Chronic myeloid leukaemia relative survival proportions: period of diagnosis, females, Australia

Years after diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
1	72.3	70.1–74.5	73.9	69.5–78.2	71.5	67.4–75.7	71.9	68.7–75.2
2	58.9	56.5–61.4	59.6	54.6–64.6	57.4	52.8–62.1	59.5	55.9–63.2
3	48.3	45.7–50.9	48.2	43.0–53.3	44.8	40.1–49.5	50.7	46.9–54.5
4	41.2	38.6–43.9	40.7	35.6–45.9	36.2	31.6–40.9	45.3	41.2–49.3
5	34.8	32.1–37.5	32.1	27.2–37.0	30.9	26.4–35.5	39.9	35.6–44.3
6	28.7	26.1–31.4	26.1	21.4–30.8	24.7	20.3–29.0	34.8	30.0–39.5
7	24.9	22.2–27.6	21.3	16.8–25.8	21.9	17.7–26.1	31.5	25.9–37.0
8	21.6	18.9–24.4	18.5	14.2–22.8	19.1	15.0–23.2		
9	19.8	17.0–22.6	16.1	11.9–20.3	18.3	14.2–22.5		
10	18.0	15.1–21.0	13.8	9.8–17.8	17.7	13.5–22.0		
11	17.8	14.7–20.8	14.0	9.9–18.1	16.8	12.3–21.2		
12	17.5	14.4–20.7	13.5	9.4–17.6	17.4	12.8–22.0		
13	16.2	12.8–19.6	12.2	8.2–16.3				
14	16.9	13.3–20.4	12.7	8.6–16.9				
15	16.7	12.8–20.5	12.6	8.3–16.9				

Table 23.23: Chronic myeloid leukaemia five-year relative survival proportions: age at diagnosis by period of diagnosis, males, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	22.3	4.2–40.4	14.3	0.0–40.4	*		50.2	21.8–78.5
5–9 years	60.1	29.7–90.5	33.4	0.0–86.8	80.1	45.0–100.1	50.0	0.0–100.1
10–19 years	61.8	47.3–76.3	50.3	19.1–81.5	75.4	54.1–96.7	58.2	35.9–80.5
20–29 years	53.0	43.9–62.1	47.2	29.8–64.6	52.7	37.5–67.9	58.4	43.7–73.1
30–39 years	50.9	43.3–58.5	43.2	29.2–57.2	45.8	32.6–59.1	61.3	49.6–72.9
40–49 years	48.9	41.6–56.2	30.3	17.0–43.6	53.2	40.7–65.7	59.2	48.6–69.8
50–59 years	33.6	27.6–39.7	22.5	13.3–31.7	31.2	20.3–42.1	46.0	35.9–56.2
60–69 years	27.3	22.8–31.7	17.5	10.8–24.2	38.8	30.7–46.9	23.7	16.1–31.3
70 years and over	20.8	17.6–24.0	15.4	9.7–21.2	21.4	15.8–27.1	22.8	17.7–27.8
All ages	32.3	30.1–34.5	23.7	19.9–27.5	35.5	31.5–39.4	35.8	32.2–39.5

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.

Table 23.24: Chronic myeloid leukaemia five-year relative survival proportions: age at diagnosis by period of diagnosis, females, Australia

Age at diagnosis	1982–1997		1982–1986		1987–1991		1992–1997	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
0–4 years	60.7	33.6–87.9	33.4	0.0–86.8	66.9	13.4–100.4	71.6	38.0–100.2
5–9 years	50.0	1.0–99.1	*		*		50.0	0.0–100.1
10–19 years	38.8	16.7–60.8	37.6	4.0–71.2	60.1	17.1–100.2	23.5	0.0–60.8
20–29 years	51.2	39.6–62.8	56.4	32.0–80.8	44.5	25.8–63.3	54.4	36.0–72.9
30–39 years	58.0	48.8–67.2	42.7	27.3–58.1	74.5	59.0–90.0	63.6	49.5–77.7
40–49 years	44.3	36.0–52.5	31.8	16.2–47.4	45.9	32.6–59.2	50.8	37.3–64.3
50–59 years	35.8	28.6–42.9	34.4	21.4–47.4	24.7	13.5–36.0	46.9	35.2–58.5
60–69 years	33.1	27.1–39.1	27.6	18.1–37.2	25.4	15.1–35.6	44.0	33.6–54.4
70 years and over	25.2	21.4–29.1	27.1	19.0–35.2	19.7	13.6–25.7	27.9	21.9–33.9
All ages	34.8	32.1–37.5	32.1	27.2–37.0	30.9	26.4–35.5	39.9	35.6–44.3

* The relative survival estimates indicated by * showed considerable statistical instability making interpretation difficult. The instability in this age/sex/site group may be due to the survival model's handling a combination of small number of cases/deaths and or unstable background survival patterns resulting in invalid estimates. These results are therefore not presented here.